Document:

First Amendment and Supplement dated November 15, 2005

 EXHIBIT 10.56 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO
RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 EXHIBIT A 
 FIRST AMENDMENT AND
SUPPLEMENT (“this Amendment”) dated as of November 15, 2005 to the DEVELOPMENT AND LICENSING AGREEMENT (“the Original Agreement” and, as amended and supplemented by this Amendment, “the Agreement”) dated as of
September 27, 1996, by and between GILEAD SCIENCES, INC., a Delaware Corporation (“Gilead”), on the one hand, and F. HOFFMANN-LA ROCHE LTD, a corporation organized under the laws of Switzerland, and HOFFMANN-LA ROCHE INC., a
corporation organized under the laws of New Jersey, on the other hand (collectively “Roche”). Capitalized terms used but not defined herein shall have the meanings assigned them in the Original Agreement. 
 WHEREAS pursuant to the Original Agreement Gilead granted to Roche and its Affiliates, among other things, a sole and exclusive worldwide license under
certain intellectual property rights only for the manufacture, importation, use, sale and offer for sale of Products for any and all uses on the terms set forth therein; 
 WHEREAS pursuant to a Settlement Agreement and Release executed by the parties as of the date hereof (“the Settlement Agreement”) the parties have resolved all disputes that have arisen under the Original
Agreement and have agreed to execute this Amendment; 
 NOW, THEREFORE, in consideration of the foregoing premises and the covenants and
obligations set forth in this Amendment, the parties hereby agree as follows: 
 Section 1. Amendment of Original Agreement.

 (a) Deletion Of Redundant Provision. Article 4 of the Original Agreement is hereby amended by deleting Section 4.4 of the
Original Agreement in its entirety and substituting therefor the word “Reserved”. 
 (b) Elimination Of Cost Of Goods Sold
Adjustment. Article 5 of the Original Agreement is hereby amended by deleting Section 5.3(d) of the Original Agreement in its entirety and substituting therefor the word “Reserved.” Notwithstanding anything in the Original
Agreement to the contrary, no pending or future Royalty payments to be made by Roche to Gilead under the Agreement shall be subject to any reduction relating to any “COGS Adjustment Amount” and Gilead shall not be entitled to any recovery
relating to any “COGS Adjustment Amount”. 

 (c) Modification of Royalty Payment Schedule: Article 5 of the Original Agreement is hereby
amended by replacing 5.3(b) with the following: “Roche shall pay Gilead the Royalty owing to Gilead at the rates set forth in section 5.3(a) of the Original Agreement. By way of example, if, in the calendar year 2006, Roche’s total
calendar 2006 Net Sales is equal to $700 million, and the fourth quarter of calendar 2006 Net Sales is equal to $150 million, the total Royalty Payment from Roche to Gilead related to Net Sales in the fourth quarter of calendar 2006 shall equal $33
million (22% of $150 million). And if, in the first quarter of calendar 2007, Net Sales is equal to $250 million, then the Royalty Payment from Roche to Gilead related to Net Sales in the first quarter of calendar 2007 shall equal $37 million (14%
of the first $200 million, and 18% of the next $50 million).” 
 Section 2. Sale and Purchase of shikimic acid: Roche
agrees to purchase from Gilead, and Gilead agrees to sell to Roche, a specific quantity of shikimic acid as set out in Attachment 1 (the “shikimic acid”) for a total purchase price of [ * ] (the “Purchase Price”) and on
the following terms: (i) Gilead shall deliver the shikimic acid to Roche to the location or locations specified by Roche to Gilead, as soon as reasonably practicable and no later than [ * ] after the date of this Amendment;
(ii) together with delivery of the shikimic acid, Gilead shall provide to Roche certificates of analysis and samples to determine usability in respect of each batch of the shikimic acid; (iii) Roche shall pay Gilead the Purchase Price
within [ * ] of delivery of the shikimic acid; and (iv) Gilead warrants to Roche that the shikimic acid shall be useable and free from defects [ * ]. 
 Section 3. Communication Regarding Public Health Initiatives. 
 (a) Coordination
of Communications. Roche shall through the Commercial Working Group (as defined in Section 6(f)) use its good faith reasonable efforts to keep Gilead reasonably informed of Roche’s key message points and communications strategies
regarding the Product and Product positioning, and Roche shall consider in good faith Gilead’s input and comment regarding such message points and strategies. Gilead shall use its good faith reasonable efforts to ensure that its public
communications are consistent with such message points and strategies, including with respect to (i) engaging in public health initiatives relating to the Product and other educational initiatives relating to the Product for the medical and
scientific communities, (ii) developing and discussing treatment guidelines and protocols relating to the Product and (iii) communicating with public health advocates on scientific and medical matters relating to the Product. 

 

 2 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 (b) Roche’s Exclusive Right to Communicate with Regulatory and Governmental Authorities.
Roche retains the exclusive right under the Original Agreement to sell, offer for sale and otherwise promote the Product to potential government purchasers in the United States and around the world, and has the exclusive right to communicate
with governmental and regulatory authorities (including the FDA) regarding regulatory and commercial issues (including governmental licenses and/or approvals to market the Product) associated with the Product. Roche understands, however, that Gilead
will be communicating with government agencies, public officials and members of the public health, medical and scientific communities in the course of carrying out the types of activities described in the final sentence of Section 1(a) above.

 Section 4. Coordination With Respect To Voluntary And Compulsory Licensing. 
 (a) General Strategy. The parties shall collaborate and attempt in good faith to develop and review on an ongoing basis a strategy for responding
to threats of compulsory licensing of the Product and for related requests by Third Parties for sublicenses to make, use and sell the Product under circumstances other than normal commercial circumstances (a “Voluntary License”). Such
collaboration shall be arranged through representatives from each party who shall be designated by Roche and Gilead in writing. Nothing in this Amendment shall affect Roche’s pre-existing right to grant sub-licenses under Article 2 of the
Original Agreement. 
 (b) Communication with Gilead. Gilead acknowledges that Roche will be responsible for responding to requests
for Voluntary Licenses and for communications with governments regarding compulsory licensing of the Product. Each party shall use reasonable efforts to inform the other through its designated representative as to material developments regarding
Voluntary License proposals and threats of compulsory licensing. In addition, each party will use reasonable efforts to respond to requests from the other for information regarding such proposals and threats. 
 (c) Voluntary Licensing Proposals. Any proposal by Roche to grant a Voluntary License shall be presented promptly to Gilead for review. The
parties will work together promptly in good faith to reach agreement as to such proposal. Gilead shall advise Roche of its agreement or objection to Roche’s proposal (including the reasons for any objections) within [ * ] of the notice
by Roche. Any disagreement with respect to such a proposal (a “Voluntary License Dispute”) will be resolved promptly through the applicable dispute resolution 

  

 3 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
procedures set forth in Sections 10(e) and 11 hereof. A Voluntary License to which Gilead has consented in writing or to which the arbitrator has determined,
prior to its issuance, is not unreasonable shall be referred to as an Apportioned License. 
 (d) Apportionment of Licensing
Consideration. Consideration, if any, paid by the licensee under either an Apportioned License or compulsory license of the Product shall be shared 50% by Roche and 50% by Gilead, and any sales by Third Parties under any such licenses (and the
related payments under this clause (d)) [ * ]. 
 Section 5. Joint Manufacturing Committee. 
 (a) Formation of Committee. Gilead and Roche shall form a Joint Manufacturing Committee (“the Manufacturing Committee”) with two
representatives designated by Gilead and two representatives designated by Roche. The initial representatives to the Manufacturing Committee from each party are set forth in Schedule 5(a). Either party may replace its representatives at any time
upon written notice to the other party, provided such replacement representative is of similar status and authority as the representative being replaced. 
 (b) Responsibilities of the Manufacturing Committee. The Manufacturing Committee shall be responsible for (i) reviewing Roche’s existing worldwide capacity for Product manufacture currently in place
and plans for the expansion of such capacity consistent with Roche’s obligations under the Agreement; and (ii) considering and evaluating Roche’s global plans for manufacturing the Product (“Roche’s global manufacturing
plans”) consistent with Roche’s obligations under the Agreement. The Manufacturing Committee shall also review Roche’s efforts to make process improvements such as improvements in equipment throughput and yield efficiencies. Roche
shall provide Gilead with a report on Roche’s global manufacturing plan reasonably in advance of each scheduled meeting of the Manufacturing Committee, and in any event at least [ * ] in advance of the meeting, which report shall include
information about current and anticipated manufacturing requirements and capacity, sources of supply, and process improvements such as improvements in equipment throughput and yield efficiencies with respect to the Product (inclusive of raw
materials and intermediates). 
 (c) Procedures of the Manufacturing Committee. The Manufacturing Committee shall meet in person on a
quarterly basis for the first two years following the execution of this Amendment, and thereafter on a semi-annual basis, and shall attempt in good faith to reach consensus on all issues. Meetings 

  

 4 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
of the Manufacturing Committee shall be held in [ * ], with [ * ] meetings held in [ * ] and the [ * ] meeting held in [ *
]. The first meeting shall be held in [ * ]. In the event that the Gilead representatives disagree with Roche’s plans or any aspect thereof, Gilead shall have the right to appeal the determination of the Roche representatives through
the applicable dispute resolution procedures set forth in Sections 9 and 10 of this Amendment. Each of Gilead and Roche may advise the other if it desires the agenda for any meeting of the Manufacturing Committee to include reasonable topics beyond
those which are evident from the report submitted to it in advance by the other. Each party shall supply to the other any information related to Product manufacture which is reasonably requested by the other party, without placing undue burden on
the supplying party consistent with the responsibilities of the Manufacturing Committee. 
 (d) Formation of Manufacturing Working Group;
Informal Communications. In addition to forming the Manufacturing Committee, Gilead and Roche shall each appoint three individuals to a Manufacturing Working Group. The initial representatives to the Manufacturing Working Group from each party
are set forth in Schedule 5(d). Either party may replace its representatives at any time upon written notice to the other party, provided such replacement representative is of similar status and authority as the representative being replaced. The
Manufacturing Working Group shall meet on a regular basis to exchange information regarding the development of Roche’s global manufacturing plan, activities and progress under such plan (such as reviewing existing inventory levels versus
current demand forecasts) and manufacturing issues related to the Product. Meetings of the Manufacturing Working Group (“Manufacturing Working Group Meetings”) shall be held on such schedule as the members of such working group may jointly
agree, provided, however, that each of Gilead and Roche shall make its representatives available to participate in Manufacturing Working Group Meetings at least once per month, for meetings of at least two hours in length. Each party
may provide agenda items to the other party in advance of each meeting of the Manufacturing Working Group. Manufacturing Working Group Meetings shall be held by telephone or video conference unless the Gilead and Roche representatives mutually agree
otherwise. 
 Section 6. U.S. Commercial Committee. 
 (a) Formation of Committee. Gilead and Roche shall form a U.S. Commercial Committee (“the Commercial Committee”) with two representatives
designated by Gilead and two representatives designated by Roche. The initial representatives to the Commercial Committee from each party are set forth in Schedule 6(a). Either party may replace its representatives at any time upon written notice to
the other party, provided such replacement representative is of similar status and authority as the representative being replaced. 
  

 5 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 (b) Responsibilities of the Commercial Committee. The Commercial Committee shall be responsible
for considering and evaluating Roche’s commercial plans and strategies for the Product in the United States (“Roche’s U.S. commercial plans”) consistent with Roche’s obligations under the Agreement. The Roche U.S. commercial
plans shall consist of the “plan of action” used by Roche for its internal planning purposes, which shall address in reasonable detail at least the topics identified on Attachment 2 to this Amendment. Roche shall provide Gilead with a
report on Roche’s U.S. commercial plans reasonably in advance of the scheduled pre-season meeting of the Commercial Committee, and in any event at least [ * ] in advance of the meeting. Nothing in this Amendment shall in any way affect
or modify Roche’s exclusive rights under Article 7.1 of the Original Agreement. 
 (c) Marketing Presentations. The Commercial
Committee shall meet in person twice per year [ * ]. One meeting shall be a “pre-season meeting” to be held early in [ * ]. Roche shall use its reasonable efforts to deliver to Gilead at least [ * ] in advance of such
meeting a copy of the U.S. marketing “plan of action” used by Roche for its internal planning purposes, which shall set forth at least the information described above with respect to Roche’s U.S. commercial plans, and such plan of
action shall include an analysis assessing in reasonable detail U.S. sales and marketing progress against the activities and targets set forth in the prior year’s plan. The other meeting shall be a mid-season review to be held early in [ *
]. The mid-season review shall among other things assess U.S. sales and marketing progress against the activities and targets set forth in the pre-season plan. Roche shall present to Gilead at least [ * ] in advance of such mid-season
meeting a report setting forth in reasonable detail such progress against the pre-season plan. 
 (d) Utilization of Gilead’s Sales
Force. Gilead shall have the option to provide a specialized sales force of no more than 200 representatives (e.g. a specialty sales force such as pediatrics) to supplement Roche’s marketing efforts in the United States for the
Product as provided in this paragraph (the actual number of representatives at Gilead’s election up to 200). Gilead may exercise such option by providing written notice to Roche which shall include Gilead’s determination of appropriate
sales force involvement. The Commercial Committee shall determine the appropriate type of specialty sales force that will be utilized; including determining, in good faith, which type of sales force would most effectively enhance sales of the
Product. In doing so, the Commercial Committee will seek to avoid duplication or overlap with the sales efforts of Roche’s U.S. sales force or its contract sales organizations. If the Commercial Committee cannot avoid duplication or overlap, it
will seek to minimize such duplication or overlap. The Commercial Committee may not, without Gilead’s written consent, reduce the number of representatives elected by Gilead. The 

  

 6 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
parties will negotiate reasonable fee-for-service compensation based on such Gilead sales force achieving agreed-upon activity levels (such as the number of
details performed). Such fee-for-service compensation shall be in addition to the royalties payable under the Agreement. In the event Gilead exercises such option, the parties shall promptly negotiate in good faith a definitive co-promotion
agreement giving effect to the foregoing and containing such other commercially reasonable, arm’s length terms consistent with the foregoing as are customary in the industry for the promotion of pharmaceutical products. Upon the execution and
delivery of such definitive agreement, this sub-section (d) shall be superseded by such definitive agreement. 
 (e) Procedures of
the Commercial Committee. The Commercial Committee shall attempt in good faith to reach consensus on all issues. In the event that the Gilead representatives disagree with Roche’s U.S. commercial plans or any aspect thereof or with the
Commercial Committee’s determination of the appropriate involvement of the Gilead specialty sales force, Gilead shall have the right to appeal the determination of the Roche representatives through the applicable dispute resolution procedures
set forth in Sections 9, 10 and 11 of this Amendment. Gilead may advise Roche if it desires the agenda for any meeting of the Commercial Committee to include reasonable topics beyond those which are evident from the report submitted to it in advance
by Roche. 
 (f) Formation of U.S. Commercial Working Group; Informal Communications. In addition to forming the Commercial Committee,
Gilead and Roche shall each appoint two individuals to a U.S. Commercial Working Group (the “Commercial Working Group”). The initial representatives to the Commercial Working Group from each party are set forth in Schedule 6(f). Either
party may replace its representatives at any time upon written notice to the other party, provided such replacement representative is of similar status and authority as the representative being replaced. The Commercial Working Group shall meet on a
regular basis to exchange information regarding the development of Roche’s U.S. commercial plans and coordination between Gilead and Roche in the event Gilead exercises its option in Section 6(d). Meetings of the Commercial Working Group
(“Commercial Working Group Meetings”) shall be held on such schedule as the members of such working group may jointly agree, provided, however, that each of Gilead and Roche shall make its representatives available to participate in
Commercial Working Group Meetings at least once per month, for meetings of at least two hours in length. Commercial Working Group Meetings shall be held by telephone or video conference unless the Gilead and Roche representatives mutually agree
otherwise. 
 Section 7. Gilead Participation In Life Cycle Team. Gilead shall be entitled to designate a
representative to become a core member of Roche’s Life 

  

 7 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
Cycle Team with respect to the Product. Roche shall in good faith provide the Gilead representative with access to information regarding the Product provided
to other core members of the Life Cycle Team for purposes of Life Cycle Team Meetings, including any materials relating to the Product that are referred to or discussed in Life Cycle Team meetings; excluding in each case as to matters that Roche
reasonably and in good faith believes are proprietary business secrets unrelated to the Product, legal opinions or other privileged materials. The Gilead representative shall be entitled to participate in all Life Cycle Team meetings and phone
calls, provided, however that Roche shall have no obligation to schedule team meetings or phone calls around the availability of the Gilead representative. Through the Life Cycle Team, Roche and Gilead shall in good faith coordinate with respect to
Gilead’s participation in relevant global scientific advisory committees pertaining to the Product. 
 Section 8.
Joint Supervisory Committee. 
 (a) Formation of Committee. Gilead and Roche shall form a Joint Supervisory Committee (“the
Joint Supervisory Committee”) with three representatives designated by Gilead and three representatives designated by Roche. The initial representatives to the Joint Supervisory Committee from each party are set forth in Schedule 8(a). Either
party may replace its representatives at any time upon written notice to the other party, provided such replacement representative is of similar status and authority as the representative being replaced. 
 (b) Responsibilities of the Joint Supervisory Committee. The Joint Supervisory Committee will consider and evaluate Roche’s overall
commercial plans for the Product on a global basis (“Roche’s global commercial plan”). The Joint Supervisory Committee shall also seek to resolve any disputes of the Manufacturing Committee or Commercial Committee referred to it
pursuant to Section 9 of this Amendment. Roche shall provide Gilead with Roche’s global commercial plans reasonably in advance of each meeting of the Joint Supervisory Committee, and in any event at least [ * ] prior to the meeting,
which plans shall include historical and budgeted promotional spending levels, sales force activities, sales force size, major marketing activities, commercialization strategies, pricing strategies, forecasts and marketing analyses, in each
Specified Market and Japan. Such plans shall also set forth Roche’s activities, plans and budgets with respect to government sales and pandemic planning. In reviewing and evaluating Roche’s global commercial plans, Gilead recognizes that
activities in Japan for the Product are conducted through a majority-owned subsidiary of Roche acting under a sublicense, and that Roche’s access to information and control of activities in that country are more limited than elsewhere in the
world. Nothing in this Amendment shall in any way affect or modify Roche’s exclusive rights under Article 7.1 of the Original Agreement. 
  

 8 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 (c) Spending Levels For Seasonal Sales in Specified Markets. The Joint Supervisory Committee shall
review Roche’s annual budget for aggregate spending in Specified Markets on promotional, marketing and sales activities for the Product related to Seasonal Sales. As used herein, the “Specified Markets” shall mean the 10 countries
comprising the top 10 commercial markets for the Product (excluding Japan). “Seasonal Sales” shall mean sales of the Product during influenza season, excluding purchases and stockpiling by governmental or regulatory authorities and Third
Parties for pandemic planning. 
 (d) Budgeting. Roche’s ordinary course accounting and budgeting processes, procedures and
calculations shall be utilized for all purposes under this Amendment. The parties acknowledge that the amount actually spent by Roche on marketing, promoting and selling the Product in Specified Markets may, consistent with Roche’s Best Efforts
obligations under the Original Agreement, vary from the budgeted amount based upon circumstances that arise during the year or matters not otherwise within the reasonable control of Roche; it being understood and agreed that (i) any variance
from budget of less than 10% of the aggregate budgeted amount shall be deemed to be immaterial for purposes of this Amendment and (ii) a variance from budget of 10% or more shall not by itself be deemed to be a violation of Roche’s
obligations under this Amendment or the Agreement. 
 (e) Procedures of the Joint Supervisory Committee. The Joint Supervisory
Committee shall meet in person on a semi-annual basis, or on such further occasions as set forth in Section 8(f), as either Roche or Gilead reasonably may request, and shall attempt in good faith to reach consensus on all issues. Meetings of
the Joint Supervisory Committee shall be held in [ * ], with [ * ] and the [ * ]. The parties shall endeavor to schedule the semi-annual meetings of the Joint Supervisory Committee following a meeting of the Manufacturing
Committee and the Commercial Committee. If Gilead believes there are topics that should be taken up by the Joint Supervisory Committee which are not covered by the Roche report delivered to it in advance of such meeting, Gilead may add such
reasonable topics to the agenda by notice to Roche. In the event that the Gilead representatives disagree with Roche’s plans or any aspect thereof, Gilead shall have the right to appeal the determination of the Roche representatives to the
respective designated executive officers for Roche and Gilead as set forth in Section 10. 
 (f) Informal Communications. The
representatives of Gilead and Roche on the Joint Supervisory Committee shall be reasonably available during the course of the year for informal communications regarding matters within the ambit of the Joint Supervisory Committee, including the
informal resolution of issues arising within the Manufacturing Committee and Commercial Committee. 
  

 9 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Section 9. Right To Escalate Disputes To The Joint Supervisory Committee.

 (a) Escalation to JSC. In the event that the Manufacturing Committee or the Commercial Committee is unable to reach consensus on any
matter relating to the Product, Gilead shall have the right to escalate the dispute for attempted resolution by good faith negotiations among the members of the Joint Supervisory Committee. Any such escalation of a dispute must be made in writing
within [ * ] after either party has notified the other in writing that it believes that an impasse has been reached on such matter by the Manufacturing Committee or the Commercial Committee, and if Gilead does not escalate such dispute,
Roche’s position shall prevail. 
 (b) Procedure for Referring Disputes to the Joint Supervisory Committee. If Gilead wishes to
refer a dispute to the Joint Supervisory Committee, Gilead shall provide written notice to Roche and to the Joint Supervisory Committee describing the background to the dispute and the resolution it seeks (“the Notice of Dispute”) and
shall include in the Notice of Dispute all materials it wishes to advance in support of its proposed resolution. Roche shall have [ * ] to provide its written response to Gilead and to the Joint Supervisory Committee. 
 (c) Consideration by the Joint Supervisory Committee. At such time as either Roche or Gilead reasonably may request, but in any event no later
than at the next regulatory scheduled meeting of the Joint Supervisory Committee, the Joint Supervisory Committee shall consider the viewpoints of each of Gilead and Roche and shall attempt, in good faith, to resolve the dispute. 
 Section 10. References To Executive Officers. 
 (a) If the Joint Supervisory Committee is unable to resolve a dispute (other than a Voluntary License Dispute) referred to it by Gilead within the earlier of (i) [ * ] after its first meeting to discuss
the dispute, or (ii) [ * ] after such dispute has arisen, then Gilead shall be entitled to refer the dispute, upon written notice to Roche, to the executive officers of each of Roche and Gilead designated below, or their successors, who
shall attempt, in good faith, to resolve the dispute. Any such escalation of the dispute must be made within [ * ] of the failure of the Joint Supervisory Committee to resolve the dispute within the period described in this paragraph, and if
Gilead does not escalate such dispute, Roche’s position shall prevail. 
  

 10 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 (b) The said designated executive officers are as follows: 
 For Roche: CEO of Pharma Division 
 For Gilead: Chief Executive Officer 
 (c) The designated executive officers shall have [ * ] to
attempt to resolve the dispute or such further time as they may agree. 
 (d) If the designated executive officers are unable to resolve the
dispute, and if Gilead reasonably concludes that the dispute is material, Gilead shall be entitled to refer the dispute to Gilead’s Chief Executive Officer and Roche’s Chairman, who shall attempt, in good faith, to resolve the dispute. Any
such escalation of the dispute must be made within [ * ] of the failure of the designated executive officers to resolve the dispute within the period described in paragraph (c) above and in the event Gilead does not escalate such
dispute, Roche’s position shall prevail, except as provided in clause (e) below with respect to Voluntary License Disputes. The Chief Executive Officer of Gilead and the Chairman of Roche shall have [ * ] to attempt to resolve the
dispute, or such further time as they may agree. 
 (e) Voluntary License Disputes. If the parties are unable in good faith to resolve
a Voluntary License Dispute, such dispute shall be referred directly to the Chairman of Roche and the Chief Executive Officer of Gilead who shall attempt, in good faith, to resolve the dispute. Any such escalation of a Voluntary License Dispute must
be made within [ * ] of the failure of the parties to resolve the Voluntary License Dispute within the period described in Section 4(c) of this Amendment. The Chairman of Roche and the Chief Executive Officer of Gilead shall have [ *
] to attempt to resolve the dispute, or such further time as they may agree, after which either party may initiate an arbitration proceeding pursuant to Section 11(e). In the event that a Voluntary License Dispute is not resolved as
provided in this Section 10(e) and is not arbitrated pursuant to Section 11(e) below, then the proposed Voluntary License that is the subject of such Voluntary License Dispute [ * ]. 
 (f) Final Decision-Making Authority. [ * ] consultation, coordination and input rights under this Amendment [ * ], and the parties
agree that [ * ] over all disputes relating to matters set forth in Sections 3 through 8 of this Amendment that are not Arbitrable Disputes (as defined below), after taking into account in good faith the views of [ * ] in accordance
with the procedures set forth in Sections 8, 9 and 10 hereof. Without limiting the generality of the foregoing, in the event a committee or working group created under this Amendment fails to reach consensus on any issue before it, the [ * ]
committee or working group shall have the [ * ] to determine the act or decision of the committee or working group on such issue, subject in each case to the right of Gilead to escalate disagreements as provided in this Amendment. 

 

 11 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Section 11. References To Arbitration. 
 (a) Arbitrable Disputes. The parties recognize that resort to arbitration should only occur in exceptional circumstances and with respect to
disputes concerning major commercial decisions (“Arbitrable Disputes”) as to the following matters: 
 (i) The
annual budget for aggregate spending in Specified Markets on promotional, marketing and sales activities for the Product relating to seasonal influenza (“Specified Markets Spending Disputes”), excluding Roche’s annual budget for 2006.
[ * ] in the annual budget for 2008 or later for aggregate spending in Specified Markets on promotional, marketing and sales activities for [ * ] of the budget for the immediately preceding year; and 
 (ii) A Voluntary License Dispute. 
 (b) Application of Article 14 of the Original Agreement. Arbitrable Disputes that cannot be resolved pursuant to the procedures set forth in Section 8, 9 and 10 shall be resolved through binding arbitration in accordance with
this Section 11. The streamlined arbitration procedures set forth in this Section 11 shall only apply to Arbitrable Disputes. All other disputes under the Original Agreement shall be resolved in accordance with the procedures set forth in
Article 14 of the Original Agreement. 
 (c) Selection of Arbitrator. In the event the Chairman of Roche and the Chief Executive
Officer of Gilead fail to resolve an Arbitrable Dispute referred to them under this Amendment within the applicable time period specified in Section 10, (x) in the case of a Specified Markets Spending Dispute, Gilead shall have the right
during the [ * ] immediately following such failure to notify Roche in writing that it wishes to have the dispute resolved by a single arbitrator pursuant to this Section and, in the event Gilead does not so escalate such dispute, the
position of Roche shall prevail and (y) in the case of a Voluntary License Dispute, Roche shall have the right during the [ * ] immediately following such failure to notify Gilead in writing that it wishes to have the dispute resolved by
a single arbitrator pursuant to this Section and, in the event Roche does not so escalate such dispute, then the proposed Voluntary License that is the subject of such Voluntary License Dispute shall not be granted. Within [ * ] of
Gilead’s or Roche’s, as applicable, receipt of such notice, Roche and Gilead shall deliver to each other a list of three proposed arbitrators, each with (i) at least ten 

  

 12 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 
years of significant management-level experience, or industry-specific experience as a consultant, in the pharmaceutical industry, (ii) no direct or
indirect affiliation with either party or its Affiliates or sublicensees, (iii) no conflict of interest as to the parties in general, and (iv) no direct or indirect interest in the matter in dispute. The parties shall have [ * ] to
attempt to agree in good faith on the choice of arbitrator. If no agreement is reached within such [ * ] period, each of Roche and Gilead shall be entitled to strike two of the other party’s proposed arbitrators and the remaining two
proposed arbitrators shall be submitted to the American Arbitration Association to select a single arbitrator. 
 (d) Arbitration for
Specified Markets Spending Disputes. Specified Markets Spending Disputes except for Voluntary License Disputes shall be resolved in accordance with the following procedure: 
 (i) Within [ * ] of selecting an arbitrator Roche and Gilead shall each submit to the arbitrator a proposal for the aggregate
amount of money to be spent in Specified Markets on promotional, marketing and sales activities for the coming year and written materials in support of its proposal, no longer than thirty pages in length. 
 (ii) The arbitrator may hear oral argument in New York, NY in support of each party’s position. The arbitrator shall consider only
the parties’ submissions, any oral arguments and the text of the Agreement and this Amendment, and shall select either Roche’s proposal or Gilead’s proposal and, to the extent Article 2 and Article 4 of the Original Agreement is
applicable, the arbitrator shall select the proposal that most closely conforms to Roche’s obligations under the Original Agreement to use Best Efforts. Neither party shall engage in ex parte communications with the arbitrator. The parties
shall use reasonable efforts to obtain the decision of the arbitrator within [ * ] after his/her selection. 
 (e) Arbitration for
Voluntary License Disputes. 
 (i) The parties recognize the need to resolve Voluntary License Disputes on an expedited
basis. Following execution of this Amendment, the parties shall work together to identify an arbitrator with suitable experience to nominate as the proposed arbitrator for such disputes. The selection criteria as determined in paragraph (c) of
this Section shall apply accordingly. 
 (ii) Voluntary License Disputes shall be resolved in accordance with the Commercial
Arbitration Rules of the American Arbitration Association, and, to the extent practicable, those rules governing expedited procedures. The parties shall use reasonable efforts to obtain the decision of the arbitrator within [ * ] after
his/her selection. 
  

 13 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 (iii) A proposal by Roche to grant a Voluntary License shall be upheld unless such
proposal is determined by the arbitrator to be unreasonable. 
 (f) Effect of Arbitrator’s Award. An arbitral award issued
pursuant to this Section 11 shall be final and binding upon the parties and not subject to appeal and otherwise have the effects specified in the Agreement. The parties shall promptly implement any arbitral award. 
 (g) Restriction on Number of Arbitrations. If Gilead is the losing party in an arbitration relating to a Specified Markets Spending Dispute, it
shall forfeit the right to trigger an arbitration with respect to that category of dispute for [ * ]. In the event Gilead is the losing party in two consecutive arbitrations relating to a Specified Markets Spending Dispute, Gilead shall
forfeit the right to bring an arbitration under this Section with respect to any further Specified Markets Spending Disputes for [ * ]. The forfeits described in this Section 11(g) shall not apply if in a given annual global spending
period, Roche decreases budgeted spending in Specified Markets by more than [ * ]. 
 Section 12.
Representations And Warranties. Each party hereby represents and warrants: (a) such party is duly organized and validly existing under the laws of the state of its incorporation and has full corporate power and authority to enter into
this Amendment and to carry out the provisions hereof; (b) such party is duly authorized to execute and deliver this Amendment and to perform its obligations hereunder; (c) this Amendment, and the Original Agreement as amended and
supplemented hereby, is a legal and valid obligation binding upon it and is enforceable in accordance with its terms; (d) the execution, delivery and performance of this Amendment by it does not conflict with any agreement, instrument or
understanding, oral or written, to which it is a party or by which it may be bound and does not violate any law or regulation or any court, governmental body or administrative or other agency having authority over it. 
 Section 13. Effectiveness. The amendments and supplements to the Original Agreement set forth in this Amendment shall be
effective on the date that each of the parties hereto shall have received executed counterparts of this Amendment which, when taken together, bear the signatures of Roche and Gilead. 
 Section 14. Amendments. No amendment or modification of this Amendment shall be valid or binding upon the parties unless made
in writing and signed by each party. 
  

 14 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Section 15. Waiver. No waiver by any party hereto on any breach or default of
any of the covenants or agreements herein set forth shall be deemed a waiver as to any subsequent or similar breach of default. 
 Section 16. Agreement. The Original Agreement, as amended and supplemented by this Amendment, is hereby incorporated herein by reference and shall be and become part of this Amendment as if set forth herein in its
entirety. After the date hereof, any reference to the Original Agreement shall mean the Agreement as amended and supplemented hereby. Except as specifically set forth herein, this Amendment shall not by implication or otherwise alter, modify, amend
or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Agreement, all of which are ratified and affirmed in all respects and shall continue in full force and effect. 
 Section 17. Entire Agreement. The Agreement as amended and supplemented by this Amendment, and all Exhibits and Schedules
referred to in herein or therein, together with the Settlement Agreement, embody the entire understanding of the parties with respect to the subject matter hereof and shall supersede all previous communications, representations or understandings,
either oral or written, between the parties relating to the subject matter hereof. 
 Section 18. Governing Law.
This Amendment is made in accordance with and shall be governed and construed under the laws of the State of California, as such laws are applied to contracts entered into and to be performed within such state. 
 [remainder of page left blank] 
  

 15 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their duly
authorized representatives as of the date first above written. 
  

			
	 F. HOFFMANN-LA ROCHE LTD

		
	 By:
	 	 /s/ William Burns

	 Name:
	 	William M. Burns
	 Title:
	 	CEO Division Roche Pharmaceuticals
		
	 By:
	 	 /s/ Stefan Arnold

	 Name:
	 	Stefan Arnold
	 Title:
	 	Deputy Director and Legal Counsel
	
	 HOFFMANN-LA ROCHE INC.

		
	 By:
	 	 /s/ Frederick C. Kentz

	 Name:
	 	Frederick C. Kentz, III
	 Title:
	 	 Vice President, Secretary,
 and General Counsel

	
	 GILEAD SCIENCES, INC.

		
	 By:
	 	 /s/ John F. Milligan

	 Name:
	 	John F. Milligan
	 Title:
	 	 Executive Vice President and
 Chief Financial Officer

  

 16 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Attachment 1 
 Gilead shikimic acid Inventory and Commitments 
 Date: November 15, 2005 

[ * ] 
  

 17 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Attachment 2 
 Items To Be Included in Roche’s Commercial Plans 
  

	 	1.	Forecasts of annual and monthly Product sales, and promotional and educational expenditures 

  

	 	2.	Planning for conferences and public presentations 

  

	 	3.	Sampling and market research 

  

	 	4.	ML activities and plans 

  

	 	5.	Pricing strategies and structures 

  

	 	6.	Sizes and strategies for all field-based teams involved in promotion of the Product, including revenue goals, call frequency, and incentive compensation plans

  

	 	7.	Spending allocations by indication and marketing mix (such as advertising, direct-to-consumer activities and medical education) 

  

 18 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Schedule 5(a) 
 Manufacturing Committee Representatives 
 From Roche: 
 [ * ] 
 From Gilead: 
 [ * ] 
  

 19 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Schedule 5(d) 
 Manufacturing Working Group Representatives 
 Manufacturing Working Group: 
 From Roche: 
 [ * ]

 From Gilead: 
 [ * ] 
  

 20 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Schedule 6(a) 
 Commercial Committee Representatives 
 From Roche: 
 [ * ] 
 From Gilead:

 [ * ] 
  

 21 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Schedule 6(f) 
 Commercial Working Group Representatives 
 From Roche: 
 [ * ] 
 From Gilead:

 [ * ] 
  

 22 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Schedule 8(a) 
 Joint Supervisory Committee Representatives 
 From Roche: 
 [ * ] 
 From Gilead:

 [ * ]
                                        
         
  

 23 
 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.Restated and Amended Toll Manufacturing Agreement

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 
 EXHIBIT 10.57 
 Restated and Amended 
 Toll
Manufacturing Agreement 
 by and among 
 Gilead Sciences Limited 
 Unit 13, Stillorgan Industrial Park 
 Blackrock, Co. Dublin, Ireland 
 Gilead Sciences, Inc. 
 333 Lakeside Drive 
 Foster City, CA 94404

 USA 
 and 
 ALTANA Pharma Oranienburg GmbH 
 Lehnitzstr.
70-98 
 16515 Oranienburg 
 Germany

 RESTATED AND AMENDED TOLL MANUFACTURING AGREEMENT 
 This Restated and Amended And Restated Clinical and Commercial Supply Agreement (the “Agreement”) is entered into and made effective as of November 7,
2005 (the “Effective Date”) among, on the one hand, Gilead Sciences Limited., an Irish limited Company (“GSL”), whose registered address is Unit 13, Stillorgan Industrial Park, Blackrock, Co. Dublin, Ireland, and Gilead
Sciences, Inc, a Delaware corporation (“GSI”) with its principal office located at 333 Lakeside Drive, Foster City, CA 94404, USA (Gilead World and Gilead Sciences collectively, “GILEAD”), and, on the other hand,
Altana Pharma Oranienburg GmbH, a German corporation (“APO”) having its principal place of business at Lehnitzstrasse 70-98, 16515 Oranienburg, Germany. Gilead and APO are sometimes referred to herein individually as a
“Party” and collectively as the “Parties”. 
 WHEREAS, GILEAD is a biopharmaceutical company that discovers, develops and commercialises
therapeutics to advance the care of patients suffering from life threatening diseases worldwide; and 
 WHEREAS, GILEAD and APO are currently parties to that
certain Toll Manufacturing Agreement made effective as of August 1, 2003 with respect to the manufacture and supply of a Finished Product, (as defined below), GILEAD’s proprietary pharmaceutical product Viread® (tenofovir disoproxil fumarate); and 
 WHEREAS, GILEAD has also developed the API (as defined below) emtricitabine and has filed patents thereto and commercializes the Finished Product Truvada® (emtricitabine and tenofovir disoproxil fumarate)
either by itself or through its Affiliates on a world-wide basis; and 
 WHEREAS, Gilead Sciences will require the manufacture and supply of both Viread and
Truvada and potentially additional Finished Products in the future, and Gilead World will require the manufacture and supply of both Viread and Truvada and potentially additional Finished Products in the future for commercial distribution and sale
in the Territory; and 
 WHEREAS, APO is interested in Manufacturing the Products (as hereinafter defined) Viread and Truvada and potentially other Products
for GILEAD; 
 WHEREAS, the Parties desire to restate and amend the current Toll Manufacturing Agreement to extend and modify their arrangements for
manufacture and supply by APO of Viread for GILEAD, to provide for manufacture and supply by APO of Truvada for GILEAD, and to contemplate potential additional Bulk and/or Finished Products to be included. 
 NOW, THEREFORE, the Parties thereby agree as follows: 
 DEFINITIONS 
  

	(A)	“Affiliate” of a Party shall mean a corporation or other corporate entity that owns, is owned by or is under common direct or indirect ownership with such Party,
where “own”, “owned” and “ownership” refer to ownership of over fifty percent (50%) of the voting shares or other voting interest of such entity or the ability to control or direct management of such entity.

  

	(B)	“API” shall mean the active pharmaceutical ingredient(s) supplied by Gilead to be used by APO in the Manufacture of a Product as stated in a Product Appendix;

  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

	(C)	“[ * ]” shall mean, for an API, the [ * ] as identified as such in the applicable Product Appendix that shall be subject to [ * ] by APO pursuant to
Section 2.7 [ * ]. 

  

	(D)	“Annual Contract Order” shall mean contract orders of Gilead to APO defining commercial subjects, which are agreed between both parties and are up-dated on annual
basis. These subjects include capacity agreements as Minimum Purchase Quantities, Capacity Forecast, Reserve Capacity and agreements on pricing as Supply Prices, Idle Capacity Cost and Reserve Capacity Cost. 

  

	(E)	“Bulk Product(s)” shall mean one or more APIs in finished form as coated tablet(s) in bulk, unlabelled after completion of all processing stages up to, but not
including, final packaging as identified in a Product Appendix, having the relevant Specifications contained in Schedule “B” attached hereto; 

  

	(F)	“cGMPs” shall mean current Good Manufacturing Practices regulations promulgated by the EU Regulatory Agencies or the FDA, in respect of medicinal products as well
as by the Quality Agreement, each in their respective current versions; 

  

	(G)	“Components” means, collectively, raw materials, excipients and ingredients, required to be used in order to produce the Product in accordance with the
Specifications, other than the API, as set forth in Product Appendices. 

  

	(H)	“Confidential Information” shall have the meaning given such term in Section 15.1. 

  

	(I)	“Controlled” means, with respect to a patent, know-how or any other item of intellectual property, owned by or licensed to a Party with the ability to sublicense it
to the other Party in accordance with this Agreement, without violating or breaching any agreement with any third party. 

  

	(J)	“EU Regulatory Agency” shall mean the Regulatory Agency of the European Union or their national equivalents; 

  

	(K)	“Facility” shall mean the Manufacturing location for the Product of APO at [ * ]; 

  

	(L)	“FDA” shall mean the U.S. Food and Drug Administration, or any successor agency. 

  

	(M)	“Finished Product(s)” shall mean the fully packaged Product with all necessary product information leaflets, i.e. SPC in the saleable form as approved by the
relevant regulatory authority in the Territory 

  

	(N)	“Inventory” means all inventories of Components and work-in-process produced or held by APO in connection with the Manufacture of the Product in accordance with the
Specifications, but, for greater clarity, does not include the API; 

  

	(O)	“Know-how” shall mean the information and know-how necessary for the Manufacturing of the Product to the exclusion, however, of the manufacturing know-how for the
API; 

  

	(P)	“Manufacture” or “Manufacturing” shall mean the converting of API supplied by GILEAD or its appointee into Product by APO at the Facility,
including the required analyses and testing of API and such Products, and the packaging and dispatch labeling of such Product for shipment to GILEAD or its appointee, to the exclusion of the manufacture of API by APO. 

  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

	(Q)	“Marketing Authorization” means the authorization to market Finished Product in a jurisdiction issued by the appropriate Regulatory Agency in such jurisdiction.

  

	(R)	“Product” shall mean a bulk or packaged pharmaceutical product set forth in the product appendices. 

  

	(S)	“Product Appendix” means a Product-specific appendix to this agreements setting forth the information specified for a Product Appendix in this Agreement and any
other relevant information for such Product as agreed by the Parties. 

  

	(T)	“Quality Agreement” shall have the meaning set forth in Section 3.5. 

  

	(U)	“Release Documents” means the documentation specified pursuant to Sections 2.2.3 and 2.2.4 of the Quality Agreement that is required for GILEAD to release a batch
of Product and authorize shipment thereof. 

  

	(V)	“Specification(s)” shall mean all Manufacturing, (primary) packaging, quality assurance and release specifications in regards to Products set forth in Schedule
“C” and in regards to API set forth in individual Product Appendices; such Specifications shall be supplied by GILEAD at its sole responsibility; 

  

	(W)	“Term” shall have the meaning set forth in Section 4; 

  

	(X)	“Territory” shall mean all the countries of the world in which GILEAD has as of the Effective Date notified APO or in the future notifies APO, that Finished
Products shall be marketed, subject to Section 1.5; 

  

	(Y)	“Year” shall mean the twelve month period commencing, in the case of the first Year (regarding the remaining months) of this Agreement, on the Effective Date, and
thereafter commencing upon completion of the immediately preceding Year; 

  

	(Z)	“Working Day(s)” shall mean any working day (with the exclusion of Saturday and Sunday) on which banks are normally open in USA, and in Germany for the transaction
of business; 

 SECTION 1 
 PRODUCT SUPPLY COMMITMENTS 
 1.1 General. During the term of this Agreement, APO shall Manufacture and
supply to GILEAD the Product at the prices (the “Supply Price(s)”) indicated in Annual Contract Orders (such prices being subject to adjustment in accordance with the terms hereof), and GILEAD agrees to purchase from APO the
Products, subject to all other terms and conditions of this Agreement, at the Supply Prices shown. 
 1.2 Acceptance of Facility by Regulatory Agencies in
General. Such supply and purchase obligations shall be conditional upon acceptance of the Facility by the regulatory authorities of the Territory. With the effective date of [ * ], the EMEA has granted APO a manufacturing authorization to
Manufacture the Product. 
 1.3 Acceptance of Facility by Regulatory Agencies of the European Community. APO represents and warrants that it is the
holder of the Manufacturing authorization pursuant to Directive 75/319/EEC (as amended) and any implementation of it under the laws of Germany for the manufacturing of certain solid pharmaceutical products at its Facility. 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 1.4 Manufacturing of Product for other countries. GILEAD may elect to expand the Territory to include additional
countries and have APO Manufacture Product for such additional countries, upon which terms and conditions are to be agreed. In such case, GILEAD shall inform APO of such intention in writing and duly in advance; the Parties shall determine
the possible consequences of the Manufacture of the Product for the existing Territory, and they shall initiate the necessary steps to apply to a regulatory agency for approval of Manufacture of the Product to be placed on that market and to comply
with the applicable laws and regulations. 
 SECTION 2 
 SUPPLY OF API 
 2.1 Supply of API by GILEAD. GILEAD or an Affiliate of GILEAD
shall supply, or arrange for the supply by their contract manufacturers of, API to APO for the Manufacture of Product and APO shall Manufacture Product exclusively from API supplied by GILEAD, an Affiliate of GILEAD, or a contract manufacturer
thereof. In respect of the supply of API, the Parties agree as follows: 
 2.2 Timely Supply. GILEAD undertakes by itself or through an assignee
to timely supply API directly to the Facility as further provided hereinafter. APO shall be under no duty to Manufacture the Products (including validation batches), nor meet delivery dates provided in the Binding Orders, to the extent that GILEAD
does not supply API in a timely fashion, whether said supply is provided by GILEAD or a permitted appointee of GILEAD.  
 2.3 Conditions of Supply
and Delivery. GILEAD undertakes to supply API to APO [ * ]. All the API provided by GILEAD shall be properly packed, marked, sealed and [ * ] (Incoterms 2000) in accordance with GILEAD’s shipping and packing instructions and
with APO’s instructions for delivery, provided that at GILEAD’s request and expense, APO will provide reasonable assistance in arranging for any necessary import clearance and licenses. Delivery of API shall be made at the Facility between
9.00 a.m. and 4.00 p.m. during Working Days. 
 2.4 Certification and Incoming Inspection of API. The API delivered by GILEAD or its permitted
appointee shall be in compliance with the Specifications and any other legal requirements and shall be accompanied by a Certificate of Analysis and a Certificate of Compliance. GILEAD will include the information about gross weight, net weight and
tare weight on the label of each barrel of API. APO agrees to inspect the API delivered and to check it solely for identity, quantity and conformity with the bill of lading and, as far as reasonably possible, any damages suffered during shipping and
any other obvious defects of the API delivered within [ * ] following receipt. APO will check the gross weight of each barrel within such [ * ] period and will confirm the net weight of each barrel in the course of performing the API
weighing process for production orders. 
 2.5. Failure of API to satisfy Incoming Inspection. If the API delivered by GILEAD or its permitted
appointee to APO fails the inspections to be carried out during the [ * ] following receipt as provided under Section 2.4 above, due to a discrepancy from the bill of lading due to lack of identity or a difference in gross weight, or to
physical damages or other obvious defects, APO undertakes to notify GILEAD without undue delay in writing. GILEAD shall, upon receiving such written notice from APO, use [ * ] efforts to replace the rejected API as soon as reasonably
possible; in any event, the provisions of Section 2.9 shall apply. 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 2.6. Title to API. All API (whether being held for Manufacture or in the process of Manufacture) supplied to APO
by GILEAD or by a permitted appointee of GILEAD in accordance with this Agreement shall at all times be and remain the property of GILEAD, and shall be treated by APO in all respects as such, and shall be stored and handled in a manner to prevent
contamination by other drugs and chemicals and in accordance with GILEAD’s instructions as set forth in the Product Appendices, which GILEAD may update from time to time with APO’s approval, not to be unreasonably withheld. 
 2.7 API Lost or Destroyed. APO shall compensate GILEAD for any API lost or destroyed during the storage of API, or during the Manufacture or storage of the
Product[ * ] which will be set forth in accordance with Schedule “F” hereto, at the price defined in the applicable Product Appendix, [ * ]. In any event, it remains understood and agreed between
the Parties that APO [ * ] or is otherwise due to [ * ] as likewise set forth under the applicable Product Appendix. Upon a determination that API has been lost or destroyed such that APO is required to compensate GILEAD, APO shall[
* ]. 
 2.8. Defects of Product attributable to Defective API. With respect to defects of the Product attributable to defective API, the
provisions of Section 8.5 of this Agreement shall apply. 
 2.9. Delays in Delivery of API or Replacement Deliveries of API pursuant to
Section 2.2. If GILEAD should fail to make timely delivery of API, or of a replacement delivery of API, to APO, the provisions of Section 2.1 hereof shall apply and APO shall not be liable for any breach of its obligations hereunder
due to such events caused by GILEAD, provided, however, that APO shall be liable for any breach of its obligations due to failure to properly and timely inspect API pursuant to Section 2.4. 
 2.10 Destruction of Defective API. If API in the possession of APO is determined by the Parties to be defective, then APO will destroy it in compliance with
GILEAD’s instructions and applicable laws, rules and regulations[ * ]. 
 SECTION 3 
 MANUFACTURING LICENSE; MANUFACTURING PRODUCT BY APO 
 3.1 Manufacturing License. In relation to the grant of the Manufacturing license by GILEAD to APO for purposes of this Agreement, the Parties agree as follows: 
 3.1.1 Grant of Manufacturing License. GILEAD grants APO a non-exclusive, royalty-free, non-sublicensable, non-transferable license for the entire term of this Agreement, under all patents Controlled by GILEAD
that, but for the grant of this license, would be infringed by the Manufacture by APO of Product in accordance with this Agreement, and under all Know-how Controlled by GILEAD that is necessary or reasonably useful to the Manufacture by APO of
Product in accordance with Agreement, to Manufacture the Product at the Facility for the sole purpose of supply for the Territory of the Product so Manufactured to GILEAD, an Affiliate, or one of their contract manufacturers of Finished Product,
indicated to APO in writing duly in advance, in accordance with the terms and provisions of this Agreement. APO shall be responsible for the Manufacture of Product. 
 3.1.2 Transfer of Manufacturing and Quality Control Procedures. To the extent reasonably necessary for the exercise by APO of the rights granted by GILEAD under Section 3.1.1 hereof and to the extent not
already performed pursuant to Section 3.2 hereof, GILEAD shall make available to APO all Manufacturing and quality control procedures, including the related Know-How of GILEAD and all the other information, necessary to carry out the contracted
operations correctly in accordance with the Marketing Authorizations and any other legal requirements. 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 3.2 Validation and other Implementation Work Costs. The validation of the manufacturing process of Product and of
the analytical methods is already performed. If further validation work will be necessary, it will be charged to GILEAD based on the then-current daily rates[ * ]. 
 3.3 Manufacturing Standards. In the Manufacturing of the Product, APO agrees to adhere to (i) the quality standards and testing methods of GILEAD indicated in the Specifications;
(ii) the Quality Agreement; (iii) any other condition provided under the Manufacturing Authorisation and the Marketing Authorisation; (iv) the cGMPs; as well as (v) any additional manufacturing
standards agreed upon by the Parties in writing. Subject to what is provided under Section 10.2 below, APO agrees not to unreasonably withhold its consent to the implementation of any such additional manufacturing standards [ *
]. 
 3.4 Manufacturing Capacity. During the Term of this Agreement, APO agrees to use [ * ] efforts to allocate sufficient
Manufacturing resources in order to meet GILEAD’s requirements of the Product scheduled for delivery in accordance with Section 5 and 6 hereof. Nothing in this Section 3.4 is intended to negate APO’s obligations to fulfil Binding
Orders accepted pursuant to Section 6.3 or to prevent GILEAD from submitting aggregate Binding Orders that APO will accept, if otherwise properly submitted, for a calendar year for the applicable Yearly Minimum Volume. 
 3.5 Quality Agreement. The Parties and/or their respective Affiliates have entered or will enter into one or more agreements collectively covering all products
containing the policies, procedures, and standards by which the Parties will coordinate and implement the operational and quality assurance activities and regulatory compliance objectives contemplated under this Agreement, with Gilead Sciences
performing responsibilities for itself and on behalf of Gilead World (“Quality Agreements”).  
 SECTION 4

 TERM AND RENEWAL 
 This
Agreement shall be effective after having been signed by both Parties and shall continue in force and effect thereafter for a period of [ * ] (the “Initial Term”). After this period the term of the Agreement is extended
automatically [ * ], if the Agreement is not terminated [ * ] in advance by one Party in written form (first possible date of notice of termination[ * ].) 
 SECTION 5 
 YEARLY MINIMUM VOLUMES OF PURCHASES 

LONG TERM FORECASTS FOR PRODUCT 
 5.1.
Minimum Volumes of Purchases. GILEAD undertakes to guarantee the yearly minimum volumes of purchases of Products to be Manufactured by APO as laid down in the Annual Contract Order set forth in Schedule “A”. The Parties
will agree in good faith on yearly volumes for subsequent years on an annual basis [ * ]. In the event that Gilead does not order product to fully utilize the capacity allocated, APO will invoice Gilead for idle capacity as defined in
Schedule A, Annual Contract Order 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 5.2. Long Term Rolling Forecast for Product. Subject to what is provided under Section 5.1, for the entire
term of the Agreement, within the first [ * ] Working Days of each calendar month (“M”), GILEAD shall submit to APO its updated written long term rolling forecast for Bulk Product/Finished Product, (hereinafter the
“Long Term Rolling Forecast for Product”) showing GILEAD’s estimated requirements for the Product to be produced and delivered to GILEAD during the following [ * ] period beginning with such month M. The forecast for
months M+[ * ] through M+[ * ] shall be non-binding. 
 SECTION 6 
 PURCHASE ORDERS 
 6.1 Binding Orders for
Product. Within the first [ * ] Working Days of each month M, GILEAD shall submit to APO its written binding orders (the “Binding Orders”) for Product to be manufactured and delivered by APO in month M+[ * ]. The
Binding Orders submitted to APO shall specify GILEAD’s purchase order number, quantities of the Product, monthly delivery schedule and any other elements necessary to ensure the timely production and delivery of the Product by APO. The
quantities of Product ordered in such written orders shall be firm and binding on GILEAD and shall not be subject to reduction. 
 6.2 Binding Orders for
Product in batch size. Subject to what is provided under Section 3.4, GILEAD shall place with APO Binding Orders for Product for a full batch size or multiples thereof, as set forth in the applicable Product Appendix and modified from time
to time as mutually agreed by the Parties. It is furthermore understood by the Parties, that it is foreseen, that APO shall Manufacture the Product batches in campaigns. For all Products, the campaigns should utilize the most efficient campaign size
as mutually agreed by the parties. The parties will use reasonable efforts to distribute campaigns regularly and evenly over the calendar year. Therefore GILEAD shall consider this opportunity in its production planning and the following submission
of its Binding Orders. 
 6.3 Acceptance of Binding Orders for Product by APO. APO is obliged to accept the Binding Orders placed by GILEAD pursuant
to Sections 6.1 and 6.2 for as long as the quantities ordered do not exceed applicable Yearly Minimum Volume as defined in Schedule A: Annual Contract Order. 
 6.4 Additional Supply. APO shall use [ * ] efforts to supply Product in excess of the applicable Yearly Minimum Volume (subject to Section 3.4) and to supply Product [ * ] of GILEAD’s previous Long Term
Rolling Forecast for Product for the applicable calendar year, but shall not be obligated to supply such quantities if it is not able to do so by use of [ * ] efforts, and APO shall be allowed to take into consideration in making its
commercially reasonable decision to supply the quantity of the excess amounts APO’s Manufacturing capacity and other manufacturing commitments.  
 6.5 Addressee of Purchase Orders. All purchase orders shall be sent by GILEAD with contemporaneous telephone notification, by email or to APO to the email or fax number set forth below or identified in writing by APO: 
 ALTANA Pharma Oranienburg GmbH 
 Attention: [ * ] 
 email: [ * ] 
 Tel. No.: [ * ] 
 Fax No.: [ * ] 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 APO will acknowledge and either accept or reject purchase orders within [ * ] 
 business days of receipt to the email or fax number set forth below: 
 Attention: [ * ] 
 Email: [ * ] 
 Tel. No.: [ * ] 
 Fax No.: [ * ] 
 6.6 Prevailing Terms. To the extent the terms of any Binding Order or acknowledgement are inconsistent with the terms of this Agreement, the terms of this
Agreement shall control, and any inconsistent terms are hereby expressly rejected.  
 6.7 Reliance by APO. GILEAD understands and acknowledges
that APO will rely on the Binding Orders submitted pursuant to this Section 6 in ordering the Components required to meet such Binding Orders. In addition, GILEAD understands that to ensure an orderly supply of such Components and to achieve
economies of scale in the costs thereof, it may be desirable for APO to purchase such Components in sufficient volumes to meet the production requirements for the Product during part or all of the forecasted periods referred to in Section 5 or
to meet the production requirements of any longer period as APO and GILEAD may agree to. Accordingly, GILEAD agrees that purchases may be made by APO in respect of the Components to satisfy the production requirements for the Product for forecasted
periods to meet production requirements during such longer periods as may be agreed to in writing from time to time by GILEAD at the request of APO. If such Components are not included in the Products purchased by GILEAD within [ * ] after
the forecasted month in respect of which such purchases have been made (or such longer period as the Parties may agree), GILEAD will pay to APO [ * ] in the event such Components are incorporated into the Products subsequently purchased by
GILEAD, GILEAD will receive credit for any costs of such Components previously paid to APO by GILEAD. 
 SECTION 7

 DELIVERY 
 7.1 Terms
of Delivery of Product. Prior to delivery and shipment of Product, APO will send the Release Documents to GILEAD at the following email or, with prior notification by telephone by fax, as follows: 
 Attention: [ * ] 
 Address:
Unit 13, Stillorgan Industrial Park, Blackrock, Co. Dublin, Ireland 
 email: [ * ] 
 Fax no: [ * ] 
 Tel. no: [ *
] 
 APO will not deliver or ship until GILEAD has released the batch and authorized shipment. GILEAD will either release or reject a batch within [ *
] of receipt of the Release Documents. Product Deliveries shall be made [ * ] (as such term is defined in the Incoterms 2000) [ * ], provided that APO shall select a commercially reasonable carrier (except as
otherwise set forth below). Such title as APO has in the Products and risk of loss or of damage to the Products shall remain with APO until the Products are [ * ] at which time title and risk of loss or damage shall transfer to GILEAD in
accordance with the Incoterms 2000 [ * ] clause. APO shall, in accordance with [ * ], (i) arrange for shipping and insurance, to be paid by [ * ] and (ii) at [ * ] risk and expense, obtain any export license or
other official authorization and carry out all customs formalities necessary to export the Products. GILEAD, at its election, may select the 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 
freight carrier used by APO to ship the Products, informing APO of the name thereof reasonably in advance, and may monitor APO’s shipping and freight
practices as they pertain to this Agreement. Transport conditions shall be based upon GILEAD’s instructions for the transportation of the Products. 
 7.2 Accompanying Documentation. With each shipment of Product, APO shall provide GILEAD with the appropriate documentation, including but not limited to bills of lading, certificate of analysis and certificate of compliance. APO
undertakes, with prior notification by telephone, to email or fax to GILEAD a copy of each bill of lading to the attention of the following employee of GILEAD or as otherwise instructed by GILEAD in writing duly in advance: 
 Attention: [ * ] 
 Address:
Unit 13, Stillorgan Industrial Park, Blackrock, Co. Dublin, Ireland 
 email: [ * ] 
 Fax no: [ * ] 
 Tel. no: [ *
] 
 7.3 Short Deliveries. Subject to what is provided under Section 8.2.4 below, acceptance by GILEAD of deliveries falling short of the
quantities ordered and confirmed by APO shall be without prejudice to GILEAD’s rights in relation to any such shortage. 
 SECTION 8 
 DEFECTIVE PRODUCT 
 8.1 Defective Products. Quantities of the Product shall be deemed to be defective if such quantities do not comply with APO’s warranties under Section 13.1 hereof (the “Defective
Product(s)”) and, in relation to any such non-compliance with APO’s warranties under Section 13.1 (the “Defect(s)”). 
 8.2 GILEAD’s Duties to inspect and confirm; Implied Waiver. GILEAD agrees to inspect and confirm incoming shipments of Product as follows: 
 8.2.1 Incoming Inspection. GILEAD shall inspect, or cause its Affiliates or manufacturers to inspect, Product supplied by APO for transport damages, completeness, compliance as to quantity or timing as stated
in the Binding Orders and, as far as reasonably possible, any other obvious defects within [ * ] following receipt; GILEAD shall give APO written notice of all claims for any such obvious defect within such [ * ] period.

 8.2.2 Additional Quality Control Procedures. Thereafter, GILEAD may perform quality control procedures to be agreed between the Parties in
writing with respect to Products supplied by APO no later than [ * ] after receipt of the delivered Products in order to check if the delivered Products meet the Specifications. 
 8.2.3 Notification of Defects. GILEAD shall inform APO by prompt written communication (telex, fax) of any Defect as hereinafter defined, in any event such notice
to be received by APO in case of defects due to a discrepancy from the bill of lading due to lack of identity or a difference in gross weight, or to physical damages, other obvious defects, or defects that reasonably should be detected by any
additional quality control procedures that GILEAD may perform under Section 8.2.2 (“Detectable Defects”), within [ * ] of receipt of the Product, and, in case of other Defects, i.e. those not reasonably detectable by the
inspections in Section 8.2.1 or the procedures carried out pursuant to Section 8.2.2 (“Non-Detectable Defects”), within [ * ] of discovery by GILEAD. Any such notification of defects shall be made by notice given by
courier 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 
under the following address, or, with contemporaneous telephone notification, by either fax to the number given below or email to the address below:

 ALTANA Pharma Oranienburg GmbH 
 Quality Control Dept. 
 [ * ]

 [ * ] 
 Germany

  

	Attention:	[ * ] 

	Tel.	No.: [ * ] 

	Fax	No.: [ * ] 

	email:	[ * ] 

 8.2.4 Implied Waiver. Failure of GILEAD to inspect
or to perform agreed quality control procedures, and to notify in writing APO in the relevant time periods specified in Sections 8.2.1, 8.2.2 and 8.2.3 above of any Detectable Defect, or to notify in writing APO within the pertaining time period
specified in Section 8.2.3 above of any Non-Detectable Defect after its discovery, shall constitute a waiver of any rights relating to such Defects, unless otherwise agreed in writing. 
 8.3 Disagreement as to Defects. In the event of a disagreement between APO and GILEAD in respect of any Defects of the Product, GILEAD and APO shall conduct a
joint investigation in accordance with GILEAD’s and APO’s quality control procedures governing the re-testing of the Product, in order to determine if any Product has a Defect. Should the Parties fail to agree within [ * ] days
after receipt of GILEAD’s deficiency notice delivered to APO pursuant to Section 8.2.1 and/or Section 8.2.3 above as to whether any Product identified in such GILEAD’s notice has a Defect, the Parties shall submit a
representative sample of the rejected Product to an independent laboratory acceptable to both Parties for testing under GILEAD’s quality control procedures. The findings of such third party laboratory shall be binding upon the Parties, and if
such evaluation certifies that any Product is Defective, Sections 8.4, 8.5 and 8.6 below shall apply. The fees and expenses of such Third Party laboratory shall be borne by the Party against whom the finding is made. 
 8.4 Remedies in relation to Defective Products. Subject to Section 8.5 and subject to appropriate notification of GILEAD of potential Defects in Products in
accordance with Section 8.2 above and to a confirmation of any such Defects in accordance with Section 8.3 above due to APO’s failure to produce the Products in compliance with the Specifications and with any other warranties as
specified in Section 1.1 below, APO shall forthwith after receiving written request thereof from GILEAD (i) in case of a visible Defect, sort the rejected Product from any non-rejected Product (ii) in case of any Defect, whether
visible or not, replace the rejected Product in the next available campaign. GILEAD shall supply APO with the additional API for new batches at no additional costs for APO, provided that API quantities used to Manufacture such Defective Product
shall be subject as applicable to the compensation provisions of Section 2.7. If GILEAD reasonably determines after consultation with APO that the timing of any projected replacement by APO of rejected Product during the next available campaign
may cause GILEAD to have insufficient inventories of Product to meet its requirements for Product, GILEAD shall have the right to have another supplier provide such replacement batch of Product. Subject to the other provisions of this Agreement,
GILEAD’s remedies under this Section 8.4 shall be cumulative with other remedies it may have under this Agreement. 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 8.5 Defects of Product attributable to Deficiencies of API. Subject to what is provided under Section 2
above, APO shall have no responsibility for any Defects in the Products which are due to deficiencies of API provided that such Defects are not attributable to APO’s breach of its obligations to inspect the API delivered in accordance with
Section 2.4 above. 
 8.6 Destruction of Defective Product. If Product in the possession of APO is determined by the Parties to be defective,
then APO will destroy it in compliance with GILEAD’s instructions and applicable laws, rules and regulations, with APO to bear the expenses thereof unless the defect was determined to be due to API defects pursuant to Section 8.5.

 8.7 Limitation of Liability. Except in the circumstances where APO has failed to comply with the Specifications and any other warranties as
specified in Section 1.1, APO shall not be liable or have any responsibility for any deficiencies in, or other liabilities associated with, any Product manufactured by it, including, without limitation, any deficiencies contained in the
formulae and procedures specified by GILEAD in the Specifications and effects deriving from compliance with legal requirements as specified in Section 1.1, or which are connected to the safety, efficacy or marketability of the Products or any
distribution risk. 
 8.8 Consequential Damages. Neither Party shall be liable to the other for any consequential damages, except in the case of
Party’s gross negligence or intentional misconduct. 
 SECTION 9 
 API OR PRODUCT SHORTFALLS 
 If at any time during the Initial Term and any extension of
this Agreement, APO is or expects that it will be unable to satisfy GILEAD’ requirements of Product, in full or in part, or GILEAD is or expects that it will be unable to satisfy APO’s requirements of API, then that Party shall promptly
notify the other Party, detailing the extent to which it will not meet such requirements. Nothing in this Section 9 is intended to relieve a Party of its other obligations under this Agreement. 
 SECTION 10 
 MANUFACTURING
COMMITTEE 
 10.1 Manufacturing Committee. The Parties shall form a committee on the Effective Date to address Manufacturing issues as set out
in Clause 10.4 relating to Product Supplies to Gilead. Gilead and APO shall designate an equal number of representatives with appropriate expertise to serve as members of the Manufacturing Committee. A Party may replace its representatives serving
on the Manufacturing Committee from time to time by written notice to the other Party specifying the prior representative(s) to be replaced and the replacement(s) therefor. Gilead and APO shall select one (1) such person each to serve as joint
chairpersons of the Manufacturing Committee. The joint chairpersons of the Manufacturing Committee shall be responsible for calling meetings, preparing and circulating an agenda in advance of each meeting, and preparing and issuing minutes of each
such meeting within thirty (30) days thereafter. 
 10.2 Meetings. The Manufacturing Committee shall hold meetings at such times and places as it
elects to do so, but in no event shall it hold meetings less frequently than once every [ * ]. Meetings may be held by audio or video teleconference with the consent of each Party, provided that at least [ * ] shall be held in person
unless agreed otherwise between the Parties. Each Party shall be responsible for all of its own expenses of participating in the Manufacturing Committee. Meetings shall be effective only if at least one (1) representative of each Party is
present or participating. 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 10.3 Roles. Except as otherwise expressly provided, the role of the Manufacturing Committee shall be advisory,
with the goal of serving as a forum for the sharing of information and for the purpose of preventing, or informally resolving (if they are able to facilitate mutual agreement between the Parties) disputes between the Parties. The Manufacturing
Committee shall have solely the powers assigned to it in Clause 10.4 of this Agreement. The Manufacturing Committee shall not have any power to amend, modify or waive compliance with this Agreement. The Manufacturing Committee shall operate as to
matters within its jurisdiction by consensus, as provided in this Clause 10.3. 
 10.4 The Manufacturing Committee shall: 
  

	(A)	evaluate factors such as Manufacturing risk and Gilead’s needs for supply of Products based on Forecast Schedule and Forecasts, and, if the Manufacturing Committee determines
that such Manufacturing risks or forecasts necessitate an increase in production, then the Manufacturing Committee shall investigate the process of qualifying new equipment or scale for the Manufacture of Product. 

  

	(B)	agree, plan and implement appropriate changes to APO’s Manufacturing capacity, which may include arranging for and qualifying new equipment for the Manufacture of Product, to
enable Gilead to meet its needs for Product as indicated by Gilead’s Forecast Schedules and Forecasts in accordance with this Agreement, and determine the allocation between the Parties of the costs of such changes. 

  

	(C)	discuss, consider and, if appropriate, implement supply and demand measures as the Parties agree are appropriate to promote the objectives of this Agreement;

  

	(D)	review and discuss opportunities for the Parties to identify and implement Improvements; 

  

	(E)	perform such other functions as appropriate to further the purposes of this Agreement. 

 SECTION 11 
 PRICING AND CHANGES 
 11.1 Supply Price. APO shall Manufacture and supply the Product to GILEAD at the Supply Price set forth in the product specific appendix. Subject to
Section 11.2, the Supply Price shall be in force during the Initial Term of this Agreement. 
 No later than [ * ] APO shall be entitled to
request an adjustment to the fees for the applicable Component costs and processing fees in respect of Product for increases in manufacturing costs [ * ]. Adjusted fees will apply prospectively to fees for the following annual period.

 11.2 Changes in Manufacturing, Quality Control and Packaging of the Product. With respect to any changes of the Manufacturing, quality control and
packaging of the Product (hereinafter collectively referred to as “Change(s)”), the Parties agree with respect to the implication on the Supply Price as follows: 
 11.2.1 Changes requested by GILEAD. If GILEAD requests a Change which would result in an increase in APO’s costs for Components or for
manufacturing, controlling or 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 
packaging the Product, the Parties shall discuss in good faith what impact, if any, such Change will have on the Supply Price of the Product, and APO shall
propose in good faith a proposal that states the price change due to implementation of such a Change. If GILEAD should accept a proposed price change, the proposed Change shall be implemented, and the price change shall become effective only with
respect to those orders of the Product which are manufactured in accordance with the revised Specifications. Unless a proposed Change would cause [ * ] disruption to APO’s other operations at the Facility, APO will be obligated to
implement such Change if GILEAD accepts APO’s good faith proposal for a price change. Notwithstanding any Change in the Specifications implemented in accordance with the preceding terms of this Section 11.2.1, GILEAD agrees to purchase
[ * ] the Product manufactured by APO based upon any Binding Order relying on “old” Specification at the “old” price for those Product. In addition, GILEAD agrees to purchase [ * ] Components and Inventory utilized
under the “old” Specifications and purchased or maintained by APO in order to fulfill Binding Orders in accordance with Section 6 of the Agreement, to the extent that such Components and Inventory can no longer be utilized under the
revised Specifications. Open purchase orders for Components no longer required under any revised Specification which were placed by APO with suppliers in order to fulfill Binding Orders in accordance with Section 6 of the Agreement shall be
cancelled where possible, and where such orders are not subject to cancellation without penalty, shall be assigned to and satisfied by GILEAD. 
 11.2.2 Other Required Changes. In any event, should a Change become necessary in order to allow APO to guarantee the performance of the activities in a state of the art way or to comply with new provisions or compulsory
requests of the regulatory authorities or, in any event, with APO’s obligations under this Agreement, APO shall immediately inform GILEAD accordingly and the provisions set forth in Art. 11.2.1 above shall apply, provided, however, that
if such Change is not specific to the Product but instead relates to compliance of the Facility or APO’s general procedures with GMP, any increased costs to APO would be allocated equitably and consistently across [ * ] products
manufactured by APO at the Facility. 
 11.2.3 GILEAD shall be entitled to ask for an adjustment on prices in case of significant cost
savings for the manufacture of Products. The parties will negotiate these possible cost benefits in good faith and APO shall transfer [ * ] of the cost savings to Gilead after realisation by decreasing the Supply Price of Products
respectively 
 11.3 Capital Expenditures and Equipment. The Parties’ responsibilities and obligations under this Agreement for capital
expenditures and equipment of GILEAD to be obtained and located at the Facility for purposes of manufacture and supply of Products pursuant to this Agreement shall be as set forth in Schedule G attached hereto. 
 SECTION 12 
 PAYMENT

 12.1 Invoicing. APO shall issue invoices for the payment due from GILEAD for Product shipped to GILEAD, and all invoice amounts shall be
expressed, and all payments made in Euros. 
 12.2 Payment. Payment shall be made by GILEAD to APO within [ * ] of the date of each invoice
sent pursuant to Section 7.2. 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 12.3 Currency. Unless otherwise agreed, all monetary amounts are expressed in this Agreement in Euros.

 SECTION 13 
 GENERAL INFORMATION DUTIES 
 General Duties to inform. Each Party to this Agreement shall keep the other Party fully informed
of any notification or other information, whether received directly or indirectly which might affect the marketability, safety or effectiveness of the finished drug product or which might result in the recall or seizure of the registration / market
validation lots. 
 SECTION 14 
 WARRANTIES 
 14.1 Representations and Warranties of APO. APO makes the following representations and
warranties with respect to the Product sold hereunder: (i) the Product shall be of merchantable quality and shall fully comply with all Specifications; (ii) In Manufacturing the Product, APO shall adhere to
(a) the quality standards and testing methods of GILEAD set forth in the Specifications; (b) the Quality Agreement; (c) any other condition provided under the Manufacturing Authorization and the Marketing
Authorization; (d) the cGMPs; (e) any other applicable laws, rules and regulations applicable to manufacture of in territories where Finished Product is to be marketed, as notified by GILEAD; (f) any additional
manufacturing standards agreed upon by the Parties; as well as (g) the Binding Orders. 
 14.2 Limitation of Warranty. The above stated
warranty does not apply in the event of improper storage and/or improper handling of the Product by GILEAD or by any third party. 
 14.3 Authority.
Each Party represents and warrants that it has the full right and authority to enter into this Agreement, and that it is not aware of any impediment that would inhibit its ability to perform its obligations hereunder. 
 14.4 Formulae. GILEAD represents and warrants that the Specifications for the Product are its property and that GILEAD may lawfully disclose such Specifications
to APO. GILEAD further represents and warrants that any trademarks utilized by APO in connection with the Product are its property and may be lawfully used as directed by GILEAD. GILEAD further represents and warrants that the Specifications for the
Product conform to all applicable laws and regulations, and that the Product if labeled and formulated in accordance with such Specifications and Manufactured in compliance with this Agreement (i) may be lawfully sold and distributed in every
jurisdiction in which GILEAD markets the Product, (ii) will be fit for the purpose intended, and (iii) subject to labeling and application in accordance with applicable laws will be safe for human consumption. 
 SECTION 15 
 INDEMNIFICATION 
 15.1 Indemnification by APO. APO shall indemnify, defend and hold harmless GILEAD, its officers, directors,
agents, servants, and employees from and against any and all third party claims, demands, actions, suits or proceedings (“Third Party Claims”), arising out of APO’s breach of this Agreement (including breaches of its warranties
in Section 13.1) or APO’s negligence or willful misconduct in activities under this Agreement, and from and against all losses, damages, judgments, liabilities, costs and expenses (including reasonable legal expenses)
(“Losses”) resulting from such Third Party Claims, except in each case to the extent GILEAD has an 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 
obligation of defense or indemnity with respect to such Loss or Third Party Claim pursuant to Section 14.2. GILEAD shall not settle any such Third Party
Claim without the prior written approval of APO, and APO shall have the right, if it so wishes, to conduct negotiations to settle, settle or to conduct any litigation arising out of, any such Third Party Claim. GILEAD shall provide prompt written
notice of any such Third Party Claim to APO and shall reasonably co-operate in the defense and/or settlement of any such Third Party Claim at APO’s request and expense. 
 15.2 Indemnification by GILEAD. GILEAD shall indemnify, defend and hold harmless APO, its officers, directors, agents, servants, and employees from and against any and all Third Party Claims arising out of
(i) GILEAD’s breach of this Agreement (including breaches of its warranties in Section 13.4), (ii) for shipments of Product, the manufacture, use, import, offer for sale, sale, distribution, testing, handling, transport or
disposal of Bulk Product or Finished Product following delivery of the relevant Product pursuant to this Agreement, or (iii) GILEAD’s negligence or willful misconduct in activities under this Agreement, and from and against all Losses
resulting from such Third Party Claims except in each case to the extent APO has an obligation of defense or indemnity with respect to such Loss or Third Party Claim pursuant to Section 14.1. APO shall not settle any such Third Party Claim
without the prior written approval of GILEAD, and GILEAD shall have the right, if it so wishes, to conduct negotiations to settle, settle or to conduct any litigation arising out of, any such Third Party Claim APO shall provide prompt written notice
of any such Third Party Claim to GILEAD and shall reasonably co-operate in the defense and/or settlement of any such Third Party Claim at GILEAD’s request and expense. 
 15.3 Survival of Indemnification Obligations. The indemnification obligations set forth in this Section 14 shall survive the expiration or termination of this Agreement. 
 SECTION 16 
 CONFIDENTIALITY 
 16.1 General Principle. “Confidential Information” shall mean confidential or proprietary
information of a Party either disclosed orally or in writing to or otherwise learned by the other Party that should reasonably be known to be confidential or proprietary to the disclosing Party, including but not limited to such Party’s:
research, development, preclinical and clinical programs, data and results; pharmaceutical or biologic candidates and products; inventions, works of authorship, trade secrets, processes, conceptions, formulas, patents, patent applications, and
licenses; business, product, marketing, sales, scientific and technical strategies, programs and results, including costs and prices; suppliers, manufacturers, customers, market data, personnel, and consultants. Each Party agrees to hold in strict
confidence any and all Confidential Information of the other Party disclosed to it, to use such Confidential Information only for the purposes of this Agreement, and to restrict access to such Confidential Information to those persons entrusted to
carry out the activities provided for hereunder and who are subject to the same secrecy obligation. Each Party will protect the confidentiality of Confidential Information of the other Party using use the same level of effort it uses to protect its
own confidential or proprietary information of a similar nature but in no event less than a [ * ] level of effort. 
 16.2 Exceptions. Excepted
from the secrecy obligations in Section 15.1 shall be any Confidential Information: (i) which is in public domain at the time of disclosure; (ii) which is published or otherwise becomes part of the public domain through
no fault of the receiving Party; (iii) which was in the possession of the receiving Party at the time of disclosure as shown by prior written records; (iv) which becomes available to the receiving Party without secrecy
obligations from a third party who has the right to disclose it without breach of any obligation to the other Party; (v) or, of which the receiving Party can [ * ] prove that it was independently developed by employees of the
receiving Party who had no access to the Confidential Information disclosed. 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 16.3 Required Disclosure. Notwithstanding any other provision of this Agreement, each Party may disclose
Confidential Information of the other Party to the extent and to the persons or entities as required by applicable governmental law, rule, regulation or order (including to Regulatory Agencies for the purposes of this Agreement), provided that it
first notifies the other Party of such disclosure requirement to enable it to seek any available Excepted from this secrecy obligation shall further be Information or Know-How which has to be disclosed to the EU Regulatory Agencies for the purposes
of this Agreement or which GILEAD is entitled to disclose according to this Agreement. 
 16.4 Duration of Confidentiality Obligations. The
confidentiality obligations of the Parties shall survive this Agreement for a period of [ * ] years. 
 16.5 Improvements 
 16.5.1 APO acknowledges and agrees that it has no proprietary intellectual property rights in or to the current manufacturing process for the
Finished Product, as set forth in the Specifications. APO shall not perform any Manufacturing other than for Manufacture of Finished Product for supply to Gilead pursuant to this Agreement, and APO shall not perform any process development or
otherwise attempt to modify the Manufacturing process without Gilead’s prior written consent. 
 16.5.2 The Parties acknowledge
that they, independently or jointly, may develop improvements to the Specifications, inventions and other know-how (including without limitation data, information, processes, techniques, methods, and unpatentable inventions) in the course of
fulfilling their obligations under this Agreement (“Improvements”). Subject to Section 15.5.3, (i) APO shall own all right, title and interest in and to Improvements that are general manufacturing Improvements that have
application beyond manufacture and processing of [ * ] (including Finished Product and finished products incorporating [ * ] to the [ * ] (“APO Improvements”), and (ii) Gilead shall own all, right, title
and interest in and to all other Improvements (“Gilead Improvements”). Each Party hereby assigns its entire right, title and interest in Improvements that are to be owned by the other Party pursuant to this Section 15.5.2, and
all patents and copyrights that may be obtained thereon and trade secrets and other intellectual property rights therein (“Improvements IP”), to the other Party, and each Party will take all reasonable steps and execute and deliver
all documents reasonably required for the other Party to evidence or record such assignment as applicable. Each Party shall only use in its performance under this Agreement, its employees or consultants who have agreed in writing to assign
Improvements to it. 
 16.5.3 APO hereby grants to Gilead an irrevocable, nonexclusive, worldwide, royalty-free license under the APO
Improvements and the APO Improvements IP to research, develop, make, have made, use, sell, offer for sale, import and otherwise commercialize Gilead’s (and its Affiliates’ and licensees’) products throughout the world, with the right
to sublicense (through one or more tiers of sublicensees to Affiliates of Gilead, licensees with exclusive or co-exclusive commercialization rights to such products to in one or more countries, and contract manufacturers). 
 SECTION 17 
 TERMINATION

 17.1 Either Party’s Right to terminate for Cause. Either Party shall have the right to terminate this Agreement for cause in any of
the following events: 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 17.1.1 Termination for Material Breach. Without prejudice to any remedy or claim it may have against the other
Party for material breach or non-performance of this Agreement, either Party shall have the right to terminate this Agreement for cause in the event that the other Party fails to materially comply with or perform any material provision of this
Agreement (the “Breach”) in accordance with the following provisions: 
 (A) The terminating Party shall notify the
terminated Party of any such Breach in writing, specifying such Breach in reasonable detail and stating its intention to terminate this Agreement for cause (the “Reminder”). 
 (B) In the event that the terminated Party either (i) if the Breach is of such a nature that it can be reasonably expected to be cured within
a [ * ] period (for example, as with an obligation to make payment of monies), fails to cure such Breach within a period of [ * ] following receipt by the terminated Party of such Reminder (the “Remedy Period”), or
(ii) if the Breach is of such a nature that it cannot be reasonably expected to be cured within a [ * ] period, if the terminated Party fails to establish to the reasonable satisfaction of the terminating Party that it is
diligently and actively pursuing a cure at the expiration of such Remedy Period, , the terminating Party shall be entitled to terminate this Agreement within a period of [ * ] following the expiry of such Remedy Period with immediate effect
by giving the terminated Party related written notice. 
 (C) In the event that the terminated Party, under the circumstances referred to
under (ii) of Section 17.1.1.B above, can establish to the reasonable satisfaction of the terminating Party that it is diligently and actively pursuing a cure at the expiration of the Remedy Period, then such Remedy Period shall be
extended for so long as a cure is being diligently and actively pursued, such extension not to exceed [ * ] in the aggregate (the “Extended Remedy Period”). For clarity, the Remedy Period and the Extended Remedy Period
together shall not exceed [ * ]. 
 (D) In the event that the terminated Party shall not have cured the Breach pursuant to
Section 17.1.1.C above at the end of such Extended Remedy Period, the terminating Party may exercise its termination right for Breach within a period of [ * ] following the expiry of such Extended Remedy Period by giving the terminated
Party related written notice. 
 17.1.2 Termination for Reasons of Insolvency or Termination of Business Activities. Either Party shall be entitled to
terminate this Agreement if the other Party becomes insolvent or is subject of a petition in bankruptcy whether voluntary or involuntary or of any other proceeding under bankruptcy, insolvency or similar laws, or if this Agreement is assigned by
such other Party for the benefit of creditors. Such termination right may be exercised within a term of [ * ] following the date as of which the Party entitled to terminate receives knowledge of such insolvency or termination of business
activities by the other Party, by giving the terminated Party related written notice 
 17.1.3 Termination for Medical or Regulatory Reasons.
GILEAD shall be entitled to terminate this Agreement in case of medical or regulatory reasons which prevent the use of Finished Product in humans or in case approval of Finished Product is rejected or withdrawn by EU or foreign Regulatory
Agencies or in case of other serious safety reasons and GILEAD has undertaken serious attempts to remove the reasons therefore. 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 17.2 Financial Consequences in Case of Termination. Upon expiration or termination of this Agreement GILEAD shall,
to the exclusion of other financial obligations of GILEAD except as specifically provided for herein: (i) purchase, at APO’s cost, the Inventory applicable to the Product which was purchased, produced or maintained by APO in
contemplation of filling Binding Orders and that is suitable for production of Product; (ii) purchase from APO all undelivered Products already firmly ordered in accordance with the ordering terms of Section 6.2, at the price in
effect at the time the Binding Order was placed; and (iii) satisfy the purchase price payable pursuant to APO’s orders with suppliers of Components, provided such orders were made by APO in reliance on Binding Orders. The provisions
of this Agreement relating to delivery, acceptance, rejection and payment or and for Product shall govern delivery and purchase of such Product under (ii) and (iii). 
 If the Agreement is terminated by GILEAD pursuant to Section 17.1.1 as a result of a Breach by APO or pursuant to Section 17.1.3, GILEAD agrees to purchase such of the items referred to in (i), (ii) and
(ii) above as it determines, acting reasonably, can be used by it. 
 17.3 Return of Stocks of API. In case of the expiration or termination of
this Agreement for any reason whatsoever, APO shall, at GILEAD’s request and option, return to GILEAD or its designee or destroy all stocks of API remaining at APO, the costs of transportation or destruction to be borne by GILEAD, or, in the
case of a termination of this Agreement by GILEAD pursuant to Section 17.1.1 as a result of a Breach by APO or pursuant to Section 17.1.3, by APO. 
 17.4 Termination of Manufacturing License. Effective upon the expiration or termination of this Agreement for any reason whatsoever, the Manufacturing license granted by GILEAD to APO under Section 3.1 shall terminate, and the
rights of each Party to Information and Know-How of the other Party shall expire with immediate effect. APO shall either, at GILEAD’s option, return or destroy all Information and Know-How of GILEAD and all copies, extracts, summaries and
derivatives thereof, in its possession and shall certify to GILEAD the completion thereof. 
 SECTION 18 
 NOTICES 
 Unless otherwise specified herein, any
notice or other communication required or permitted to be given under this Agreement may be delivered personally or be sent by prepaid certified or registered post, courier or facsimile transmission (with receipt acknowledged or confirmed) addressed
to the Party addressed as follows: 
 If to GILEAD:     [ * ] 
 Gilead Sciences Inc. 
 333 Lakeside Drive

 Foster City, CA 94404 
 USA

 Fax No.: [ * ] 
 Tel.
No.: [ * ] 
 Email: [ * ] 
 with a copy to:    Gilead Sciences, Inc. 
 333 Lakeside Drive 
 Foster City, CA 94404 
 USA 
 Attention: Vice President and General Counsel 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 Fax No.: [ * ] 
 and 
 if to
APO:            [ * ] 
 Tel. No.: [ * ] 
 Fax No.: [ * ] 
 Email: [ * ]

 with a copy to:    [ * ] 
 Tel. No.: [ * ] 
 Fax No.: [ * ] 
 Email: [ * ] 
 and any such notice or other
communication shall be deemed to be effective upon receipt by the Party to which it is addressed if received during a Working Day or otherwise at the start of the next Working Day. Any Party may change the address to which notice is to be given as
provided herein by giving the other Party related written notification. 
 SECTION 19 
 DISPUTE RESOLUTION AND GOVERNING LAW 
 19.1
Disputes. In the event of any dispute, claim, question or disagreement arising out of or relating to this Agreement (a “Dispute”), the Parties shall use all reasonable efforts to settle such Dispute by amicable negotiations
within a period of [ * ] of one Party giving notice of the Dispute to the other Party. 
 19.2 Arbitration. Should the Parties not manage to
settle the dispute by amicable negotiations within the such period of [ * ], all disputes shall be finally settled under the rules of conciliation and arbitration of the International Chamber of Commerce (the “Rules”) by three
arbitrators, reasonably fluent in English, one appointed by each of the Parties and the third one, who shall act as Chairman, by the other two arbitrators, or, in the event of their failure to reach agreement within [ * ] of the appointment,
in accordance with the Rules. The arbitration procedure will take place in Geneva and will be conducted in the English language. The decision of the arbitrators will be final and binding upon the Parties. 
 19.3 Governing law. This Agreement shall be construed and enforced in accordance with the laws of Switzerland. 
 SECTION 20 
 ASSIGNMENT AND
SUBCONTRACT 
 20.1 Assignment. This Agreement may be assigned by GILEAD provided that: (i) GILEAD shall inform APO of said assignment in
writing and in advance; and (ii) any assignee shall covenant in writing with APO to be bound by the terms of this Agreement. APO may assign this Agreement to subsidiaries of APO only with prior written agreement by GILEAD which agreement shall
not be unreasonably withheld. 
 20.2 Subcontract. APO may subcontract, in whole or in part, to third parties the performance of the activities
contemplated under Section 3 above entrusted to it by this Agreement, provided that APO shall bear any additional costs possibly related to this appointment. In any event, before subcontracting the performance of the aforesaid activities to
third parties, APO must first receive written consent from GILEAD. 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 20.3 [ * ] shall be APO’s counterparty to for [ * ] supplies of Product, and [ * ] will have
the rights and obligations of GILEAD hereunder to the extent pertaining to [ * ] supplies of Products. [ * ] shall be APO’s counterparty to for [ * ] supplies of Product and will have the rights and obligations of GILEAD
hereunder to the extent pertaining to [ * ] supplies of Products. 
 SECTION 21 
 FORCE MAJEURE 
 21.1 Force Majeure.
Neither Party shall be liable for the failure to perform its obligations under this Agreement if such failure is occasioned by a cause or contingency beyond such Party’s reasonable control, including, but not limited to riots, wars, fires,
floods, storms, strikes (excluding strikes and work slow-downs that affect APO but not the German pharmaceutical manufacturing sector generally), interruption of energy supply, or compliance with any order or regulation of any government entity
which is not due to any failure or non-compliance of the Party affected. A Party claiming a right to excused performance under this Section 21 shall immediately notify the other Party in writing of the extent of its inability to perform, which
notice shall specify the occurrence beyond its reasonable control that prevents such performance and shall indicate its consequences from the stand point of the fulfilment of contractual obligations. The Party affected by an event of force majeure
must use and continue to use every effort in order to continue to perform this Agreement and, subject to the following paragraph, if absolutely necessary the Parties shall co-operate in order to agree upon terms and conditions different from those
contained herein, for the continuance of the Agreement itself for the entire period of time the event of force majeure continues. Should the event of force majeure extend for more than [ * ], each of the Parties shall be entitled to terminate
this Agreement by giving [ * ] written notice thereof to the other Party. Such notice shall indicate, inter alia, the date provided for the termination of the Agreement. 
 SECTION 22 
 WAIVER 
 A waiver of any breach of any provision of this Agreement shall not be construed as a continuing waiver of other breaches of the same or other provisions of this
Agreement. The tolerance by either of the Parties, even if continued or repeated, of breaches by the other Party of provisions contained in any clause of this Agreement shall not constitute a waiver nor it may in any way affect the validity of the
clause being breached, so long as the breach is contested within [ * ] of the date of the event by way of registered letter with return receipt. 
 SECTION 23 
 NO PARTNERSHIP 
 The relationship established hereby between GILEAD and APO is in all respects a commercial relationship. Nothing herein shall be construed as imposing any fiduciary
obligations on either Party, or as establishing any partnership or joint venture between the Parties, or as rendering one Party an agent of the other. 
 SECTION 24 
 ENTIRE AGREEMENT 
 This Agreement constitutes the entire agreement between the Parties with reference to the subject matter hereof and supersedes any prior agreements with respect to such
subject matter. Any modification, amendment or supplement to this Agreement must be in writing and signed by 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 
authorized representatives. The “WHEREAS” and the documents attached as Schedules to this Agreement form an integral and substantial part of this
Agreement. The headings to the Sections of this Agreement are for convenience only and shall be disregarded in interpreting and construing this Agreement. 
 SECTION 25 
 SEVERABILITY 
 In the event of the invalidity of any provisions of this Agreement or of this Agreement containing any gaps, the Parties agree that such invalidity or gap shall not
affect the validity of the remaining provisions of this Agreement. The Parties will in good faith replace an invalid provision or fill any gap with valid provisions, which most closely approximate the purpose and economic effect of the invalid
provision or, in case of a gap, the Parties’ presumable intentions. In the event that the terms and conditions of this Agreement are materially altered as a result of the preceding sentences, the Parties shall renegotiate the terms and
conditions of this Agreement in order to resolve any inequities. 
 SECTION 26 
 SURVIVAL 
 The termination or expiration of this
Agreement for any reason whatsoever shall be without prejudice to any obligations or rights on the part of either Party which have accrued prior to such termination, and shall not affect or prejudice the following provisions of this Agreement which
shall survive such termination or expiration: Title to API, Section 2.6; Destruction of Defective API, Section 2.10; Defective Product, Section 8; General Information Duties, Section 12; Warranties, Section 13;
Indemnification, Section 14; Confidentiality, Section 15; Financial Consequences in Case of Termination, Section 16.2; Return of Stocks of API, Section 16.3; Termination of Manufacturing License, Section 16.4; Notices,
Section 17; Dispute Resolution and Governing Law, Section 18; Waiver, Section 21; Entire Agreement, Section 23; Severability Section 24; and Survival, Section 25. 
 SECTION 27 
 EXECUTION BY COUNTERPART 
 This Agreement may be executed by the Parties in two counterparts, each of which shall be deemed an original and all of which, taken together, shall constitute one and
the same instrument. 
 IN WITNESS WHEREOF, this Agreement has been executed as of the date first above written by the Parties’ respective duly
authorized representatives. 
  

					
	Gilead Sciences Limited	 		 	ALTANA Pharma Oranienburg GmbH
			
	 /s/ Anthony Caracciolo
	 		 	 /s/ Joem-Michael Keck .

	Anthony Caracciolo, Director	 		 	Dr. Joern-Michael Keck, General Manager
			
	Gilead Sciences, Inc.	 		 	
			
	 /s/ Anthony Caracciolo     11/10/05
	 		 	 /s/ Hans-Jochim Kaatz     11/08/05

	Anthony Caracciolo, Sr. Vice President	 		 	Hans-Joachim Kaatz, General Manager

  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 Schedules to this Agreement: 
  

			
	Schedule “A”:	 	Annual Contract Order
	Schedule “B”:	 	Agreement Product Specifications
	Schedule “C”:	 	Batch Coding System
	Schedule “D”:	 	Dispatch Labeling of APO
	Schedule “E”:	 	Shipment Instructions
	Schedule “F”:	 	Manufacturing Line [ * ]
	Schedule “G”:	 	Capital Expenditure and Equipment

  

			
	Product Appendix 1:	 	Tenofovir Disoproxil Fumarate Tablets, 300 mg
		 	Exhibit A: Drug Substance and Excipient Specifications
		 	Exhibit B: Pricing Schedule
		 	Exhibit C: Manufacturing Loss Compensation Schedule
		
	Product Appendix 2:	 	Emtricitabine 200 mg and Tenofovir Disoproxil Fumarate 300 mg Tablets
		 	Exhibit A: Drug Substance and Excipient Specifications
		 	Exhibit B: Pricing Schedule
		 	Exhibit C: Manufacturing Loss Compensation Schedule
		
	Product Appendix 3:	 	[ * ] [ * ]mg, [ * ] [ * ]mg and Tenofovir Disoproxil Fumarate [ * ]mg Tablets
		 	Exhibit A: Drug Substance and Excipient Specifications
		 	Exhibit B: Pricing Schedule
		 	Exhibit C: Manufacturing Loss Compensation Schedule

  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 Schedule “A” 
 Annual Contract Order 
 between 
 Gilead Sciences Limited 
 Unit 13, Stillorgan Industrial Park 
 Blackrock, Co. Dublin, Ireland 
 Gilead
Sciences, Inc. 
 333 Lakeside Drive 
 Foster City, CA 94404 
 USA 
 (“Gilead”) 
 and 
 ALTANA Pharma Oranienburg GmbH 
 Lehnitzstr. 70-98 
 16515 Oranienburg 
 Germany 
 (“APO”) 
 1. General. This Annual Contract Order is an appendix of the Toll Manufacturing Agreement between
Gilead and APO made effective as of November 1, 2005. The parties define and agree on a rough cut capacity planning, minimum purchase quantities for a [ * ] years horizon and costs for idle capacity and reserve capacities. 
 In case of any conflict between the Toll Manufacturing Agreement and the Annual Contract Order, the content and agreements of the Toll Manufacturing Agreement shall be
binding. 
 Gilead and APO will up-date the Annual Contract Order on regular basis during [ * ] of each calendar year. The next up-date will take
place in year 2006. 
 2. Rough Cut Capacity Planning 2006-2008. 
 Gilead requires production capacities from APO for the years 2006, 2007 and 2008 as follows: 
 Table 1: Rough Cut Capacity Planning, as of Sep 2005 
  

											
	 RCCP Gilead
	  	2006	 	2007	 	2008	 	2009	 	2010
	 1. Annual Production Demand [batches] For guidance only
	  		 		 		 		 	
	 Viread {batches of [ * ] kg}
	  	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 Truvada {batches of [ * ] kg}
	  	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 Triple Combo {batches of [ * ] kg}
	  	[ * ]	 	[ * ]	 	[ * ]	 		 	
	 2. Minimum Purchase Quantity {batches of [ * ] kg equivalent}
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 3. Reserve Capacity {batches}
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 4. Total capacity requirement
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]

	*	Years 4 and 5 provided for guidance only 

  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 2.1 Minimum Purchase Quantity. 
 Gilead agrees to guarantee the yearly minimum volumes of purchases of Products as defined in Table 1, No. 2 (see also Toll Manufacturing Agreement section 5.1). 
 In return, APO will accept binding purchase orders as long as purchase volumes do not exceed [ * ] (see also Toll Manufacturing Agreement section 6.3).

 To ensure sufficient flexibility in demand planning, APO agrees to accept binding purchase orders, which [ * ] 
 2.3. Reserve Capacity. 
 APO and Gilead agree that Gilead has access
to Reserve Capacities as defined in Table 1, No. 3. For this purpose, both parties will agree on measures to ensure that sufficient equipment capacities are in place. 
 For year 2006, APO will guarantee access to reserve capacity of total [ * ] batches at existing equipment base. 
 For years 2007 and 2008, Gilead agrees that the investments in new equipment as laid down in Toll Manufacturing Agreement, Schedule G, Attachment 1 are [ * ].

 Within the Long Term Rolling Forecast (see Toll Manufacturing Agreement, section 5.2), Gilead has to inform APO in month M that Reserve Capacity shall be
utilized for production in month M+[ * ] (i.e. lead time of [ * ]). Based on this information, APO will initiate necessary measures (e.g. hiring and qualification of personnel) to realise the increase in production by month M+[ *
]. 
 In case Gilead will utilise Reserve Capacity for production, Gilead will increase the capacity demand for a time period of a [ * ].

 3. Idle Capacity Cost. 
 In the event that Gilead does
not order Product to fully utilise the capacity as defined as annual Minimum Purchase Quantity, APO will invoice Gilead for idle capacity at a rate of [ * ]. 
 APO shall issue invoices for Idle Capacity Costs to Gilead on an annual basis. 
 4. Reserve Capacity Cost. 
 In the
event that Gilead does not fully utilise the additional reserve capacity requirements within a time period of [ * ] as described in section 2.3, Gilead agrees to pay APO Reserve Capacity Costs at a rate of [ * ] (based on [ * ]
kg batches). In order to allow for planning uncertainty and flexibility, APO agrees that Gilead will only be invoiced for Reserve Capacity Cost if the volume of purchase orders is lower than [ * ] of the forecasted reserve capacity
requirements. 
 APO shall issue invoices for Reserve Capacity Costs to Gilead on an annual basis. 
  

					
	Gilead Sciences Limited	 		 	ALTANA Pharma Oranienburg GmbH
			
	 /s/ Anthony Caracciolo
	 		 	 /s/ Joem-Michael Keck        /s/ Hans-Jochim Kaatz

  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 Schedule “B” 
 Toll Manufacturing Agreement 
 Product Specifications 
 [ * ] 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 Schedule “C” 
 Toll Manufacturing Agreement 
 Batch Coding System

 Batch coding will consist of a unique alpha-numeric code of not more than 8 characters. APO will assign each lot number prior to manufacturing and
reflect that number on the purchase order confirmation sent to Gilead for the batches requested at that time. 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 Schedule “D” 
 Toll Manufacturing Agreement 
 Dispatch Labeling of APO

 The labelling of the shipping carton of Products shall include the following information: 
 [ * ] 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 Schedule “E” 
 Toll Manufacturing Agreement 
 Shipment Instructions

 [ * ] 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 Schedule “F” 
 Toll Manufacturing Agreement 
 Manufacturing Line [ * ]

 [ * ] of API [ * ] 
 1.
Manufacturing Line [ * ] 
 The Parties have set forth below the total [ * ] of API allowable per [ * ] under the Manufacturing line [ *
] after completion of the production of [ * ]. Other than in cases where APO has failed to [ * ], APO shall not be required to [ * ] GILEAD based on [ * ] or API Manufacturing line [ * ] for the [ * ]
batches. 
 In addition, the following aspects have to be considered: 
  

	 	•	 	Given that the API source might have an impact on the production process, [ * ] will be [ * ] by APO for a [ * ] API-source before [ * ] with the
API-source were produced at APO. 

  

	 	•	 	Each change of the manufacturing process, which requires a new validation and is of a nature that it is likely to change the Manufacturing line [ * ] will lead to the same
procedure and a new agreement concerning the acceptable line [ * ] as described in the product-specific appendices. In such event, the determination of the total [ * ] of API allowable per [ * ] as set forth below shall not be
changed unless it this would cause an inequitable result, in which case the Parties will agree in good faith upon an appropriate means to determine such total [ * ] allowable. If the Parties disagree as to whether a change is likely to change
the Manufacturing line [ * ], they will agree in good faith as to whether to reach a new agreement regarding acceptable line [ * ] pursuant to this Schedule “F”. 

 A. Initial Allowable Manufacturing Line [ * ] per [ * ]: the initial allowable Manufacturing line [ * ] shall be equal to [ * ] not subject
to deviation that are produced under this Agreement, minus the allowing [ * ]. 
 B. [ * ] Manufacturing Line [ * ]: At the end of every
[ * ], the allowable manufacturing line [ * ] shall be adjusted to be equal to [ * ] not subject to deviation that are produced under this Agreement [ * ] minus the [ * ] applicable at that time according to
section A. 
 C. [ * ] Arrangement: the [ * ] arrangement will start with the first batch, that is produced after the allowable manufacturing
line [ * ] has been determined based on the [ * ] batches pursuant to section A. 
 D. [ * ] Procedure: the [ * ] calculation
will consider a period of time of [ * ] by the following procedure, using the allowable Manufacturing line [ * ] determined pursuant to sections A or B as applicable: 
  

	 	i.	If the actual Manufacturing line [ * ] for batches Manufactured during an [ * ] period is [ * ] than the allowed Manufacturing line [ * ], this period
will [ * ]. 

  

	 	ii.	If the actual Manufacturing line [ * ] for batches Manufactured during the [ * ] period is [ * ] than the allowed Manufacturing line [ * ], [ * ]
pursuant to Section 2.7 for [ * ] Manufacturing line [ * ]. 

  

	 	iii.	[ * ] up to the [ * ] will be subject to [ * ] pursuant to section 2.7. 

  

	 	iv.	As the [ * ] for API may fluctuate over time, on an annual basis GILEAD may determine an adjustment to the API [ * ] to reflect such [ * ] in the [ * ]
period prior to such adjustment. Such adjusted API [ * ] shall apply under this Schedule F solely on a prospective basis. APO shall have the right to audit the methodology employed by GILEAD to determine an adjusted [ * ] for API.

  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 Schedule “G” 
 Toll Manufacturing Agreement 
 Capital Expenditure and Equipment

  

	1.	Expenditures: 

 [ * ] 
  

	2.	Equipment: 

 [ * ] 
  

	3.	Use of Equipment / Ownership Transfer 

 [ * ]

  

	4.	Maintenance of Equipment 

 [ * ]

  

	5.	Training: 

 [ * ] 
  

	6.	Title and Risk of Loss of Equipment: 

 [ * ]

  

	7.	Extra Installation Costs: 

 [ * ] 

 

	8.	Fee Adjustment: 

 [ * ] 
  

	9.	Currency: 

 [ * ] 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 Attachment 1 
 [ * ] 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 PRODUCT APPENDIX 1 – TENOFOVIR DISOPROXIL FUMARATE TABLETS 
 EXHIBIT A 
 DRUG SUBSTANCE and
EXCIPIENT SPECIFICATIONS 
 [ * ] 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 PRODUCT APPENDIX 1 – TENOFOVIR DISOPROXIL FUMARATE TABLETS 
 EXHIBIT B 
 PRICING SCHEDULE

 2006 
 [ * ]

  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 PRODUCT APPENDIX 1 – TENOFOVIR DISOPROXIL FUMARATE TABLETS 
 EXHIBIT C 
 Manufacturing [ * ]

 FOR 2006 
 [ * ]

  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 PRODUCT APPENDIX 2 – EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS

 EXHIBIT A 
 DRUG SUBSTANCE AND EXCIPIENT SPECIFICATIONS 
 [ * ] 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 PRODUCT APPENDIX 2 – EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS

 EXHIBIT B 
 PRICING SCHEDULE 
 2006 
 [ * ] 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 PRODUCT APPENDIX 2 – EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS

 EXHIBIT C 
 Manufacturing 
 [ * ] 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 PRODUCT APPENDIX 3 – EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

 TABLETS 
 EXHIBIT A 
 DRUG SUBSTANCE AND EXCIPIENT SPECIFICATIONS 
 [ * ] 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 PRODUCT APPENDIX 2 – EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

 TABLETS 
 EXHIBIT B 
 PRICING SCHEDULE 
 2006 
 (Final pricing to be set after completion of scale-up activities) 
 [ * ] 
  

	*	Pricing based on nominal batch size of [ * ]; manufacturing lot size [ * ]. 

  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 

 PRODUCT APPENDIX 2 – EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS

 EXHIBIT C 
 Manufacturing [ * ] 
 FOR 2006 
 [ * ] 
  

 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00098-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00098-of-00352.parquet"}]]